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Overview
The Centers for Disease Control and Prevention (CDC) aims to save lives and
prevent prescription opioid misuse, opioid use disorder (OUD), and overdose
by equipping providers with the knowledge, tools, and guidance they need.
The purpose of this document is to encourage careful and selective use
of long-term opioid therapy in the context of managing chronic pain through
(a) an evidence-based prescribing guideline, (b) quality improvement (QI)
measures to advance the integration of the CDC Guideline for Prescribing
Opioids for Chronic Pain (CDC Prescribing Guideline) into clinical practice,
and (c) practice-level strategies to improve care coordination. These QI
measures are intended to help incorporate the science contained in the CDC
Prescribing Guideline in clinical workflow.
This QI framework is nimble and flexible so that healthcare systems and
practice leaders can pick interventions that are responsive to the unique
conditions in their practice and patient population.

This resource covers:
Chapter One summarizes the CDC Guideline for Prescribing Opioids for Chronic Pain
in three conceptual areas:

•
•
•

Determining when to initiate or continue opioids for chronic pain;
Opioid selection, dosage, duration, follow-up, and discontinuation; and
Assessing risk and addressing harms of opioid use.

Chapter Two offers 16 clinical QI opioid measures that align with the CDC
Prescribing Guideline recommendation statements. Guidance on operationalizing
each QI measure to monitor progress is contained in the Appendix.
Chapter Three describes practice-level strategies to organize and improve the
management and coordination of long-term opioid therapy, such as:

•
•
•

Using an interdisciplinary team approach
Establishing practice policies and standards
Using electronic health record (EHR) data to develop patient registries
and track QI measures

The Toolkit contains examples of existing materials, tools, and resources
developed and used by other practices, which have been found to be useful and
readers can use or modify to their own needs. It also contains links to materials.

1

Audience for
this resource:

▶
▶
▶
▶

Primary care providers
Primary care practices
Healthcare systems
Continuous QI programs

Purpose:
Offer healthcare systems and
practices a provider-focused
resource to help move the
content of the CDC Guideline for
Prescribing Opioids for Chronic
Pain into clinical practice to
support to support providers as
they offer the best possible
healthcare to their patients.

Goal:
To ensure patients have access
to safer, more effective chronic
pain treatment by improving
the way opioids are prescribed
through an evidence-based
clinical practice guideline, while
reducing the number of people
who misuse, abuse, or overdose
from these drugs.

Chapter One

Evidence-based
Opioid Prescribing

Centers for Disease
Control and Prevention
National Center for Injury
Prevention and Control
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Introduction
CDC released the CDC Guideline for Prescribing Opioids for Chronic
Pain (CDC Prescribing Guideline) in March 2016. The Guideline offers
recommendations to primary care providers about the appropriate
prescribing of opioids to ensure patients, 18 years and older, have access
to safer, more effective treatment for chronic pain (pain lasting longer than
three months or past the time of normal tissue healing) outside of active
cancer treatment, palliative care, and end-of-life care. While prescription
opioids can be an appropriate part of pain management, the CDC Prescribing
Guideline aims to improve the safety of prescribing and reduce the harms
associated with opioids, including opioid use disorder (OUD) and overdose.
The CDC Prescribing Guideline encourages providers and patients to consider all
treatment options, particularly nonopioid and nonpharmacological therapies
that can be used alone or in combination with opioids. The CDC Prescribing
Guideline helps providers assess when it is appropriate to initiate opioid use for
the treatment of chronic pain and how to safely maintain or discontinue use in
patients who are currently on long-term opioid therapy.

Three principles
that are especially
important to
improving patient
care and safety:
1. Nonopioid and

nonpharmacologic
therapy is preferred for
chronic pain outside of
active cancer, palliative,
and end-of-life care.

2. When opioids are used,

the lowest possible
effective dosage should
be prescribed to reduce
risks of opioid use
disorder and overdose.

3. Providers should always

PRESCRIBE
WITH
CONFIDENCE.
GUIDELINE FOR
PRESCRIBING
OPIOIDS FOR
CHRONIC PAIN

3

exercise caution when
prescribing opioids
and monitor all
patients closely.
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CDC Guideline for Prescribing
Opioids for Chronic Pain
This section summarizes the 12 recommendations contained in the CDC Prescribing
Guideline. The recommendations are organized into three areas: (1) determining
when to initiate or continue opioids for chronic pain; (2) opioid selection, dosage,
duration, follow-up, and discontinuation; and (3) assessing risk and addressing
harms of opioid use.
Providers are encouraged to read the full CDC Prescribing Guideline for additional
information on improving patient outcomes, such as reduced pain and improved
function. Within the CDC Prescribing Guideline there are recommendations that are
tailored to specific populations (e.g., pregnant women, older adults) and additional
guidance on opioid therapy and tapering. The additional details provided within the
rationale statements will assist providers with improving the care and treatment of
patients living with chronic pain. Patients should receive appropriate pain treatment
based on a careful consideration of the benefits and risks of treatment options. In
treating chronic pain, providers should continue to use their clinical judgment and
base their treatment on what they know about their patients. Guidance provided
within the rationale statements equips providers with both the information they
need to empathically review and discuss benefits and risks of continued highdosage opioid therapy and the ability to offer safer, more effective chronic pain
treatment with patients.
DETERMINING WHEN TO INITIATE OR CONTINUE OPIOIDS FOR CHRONIC PAIN

Opioids are not first-line therapy.
Nonpharmacologic therapy and nonopioid pharmacologic therapy are
preferred for chronic pain. Clinicians should consider opioid therapy only
if expected benefits for both pain and function are anticipated to outweigh
risks to the patient. If opioids are used, they should be combined with
nonpharmacologic therapy and nonopioid pharmacologic therapy,
as appropriate.

Establish goals for pain and function.
Before starting opioid therapy for chronic pain, clinicians should establish
treatment goals with all patients, including realistic goals for pain and
function, and should consider how opioid therapy will be discontinued if
benefits do not outweigh risks. Clinicians should continue opioid therapy
only if there is clinically meaningful improvement in pain and function that
outweighs risks to patient safety.

Discuss risks and benefits.
Before starting and periodically during opioid therapy, clinicians should
discuss with patients known risks and realistic benefits of opioid therapy
and patient and clinician responsibilities for managing therapy.

4

clinical reminders
▶

Establish and measure
goals for improved pain
and function.

▶

Discuss benefits, risks, and
availability of nonopioid
therapies with patient.

▶

Assess pain intensity,
functional impairment,
and quality of life.
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OPIOID SELECTION, DOSAGE, DURATION, FOLLOW-UP, AND DISCONTINUATION

Use immediate-release opioids when starting.
When starting opioid therapy for chronic pain, clinicians should prescribe
immediate-release opioids instead of extended-release/long-acting
(ER/LA) opioids.

Use the lowest effective dose.
When opioids are started, clinicians should prescribe the lowest effective
dosage. Clinicians should use caution when prescribing opioids at any
dosage, should carefully reassess evidence of individual benefits and risks
when considering increasing dosage to ≥ 50 morphine milligram equivalents
(MME) per day, and should avoid increasing dosage to ≥ 90 MME per day or
carefully justify a decision to titrate dosage to ≥ 90 MME per day.

Prescribe short durations for acute pain.
Long-term opioid use often begins with treatment of acute pain. When
opioids are used for acute pain, clinicians should prescribe the lowest
effective dose of immediate-release opioids and should prescribe no greater
quantity than needed for the expected duration of pain severe enough to
require opioids. Three days or less will often be sufficient; more than seven
days will rarely be needed.

Evaluate benefits and harms frequently.
Clinicians should evaluate benefits and harms with patients within one to
four weeks of starting opioid therapy for chronic pain or of dose escalation.
Clinicians should evaluate benefits and harms of continued therapy with
patients every three months or more frequently. If benefits do not outweigh
harms of continued opioid therapy, clinicians should optimize other therapies
and work with patients to taper opioids to lower dosages or to taper and
discontinue opioids.
ASSESSING RISK AND ADDRESSING HARMS OF OPIOID USE

Use strategies to mitigate risk.
Before starting and periodically during continuation of opioid therapy,
clinicians should evaluate risk factors for opioid-related harms. Clinicians
should incorporate into the management plan strategies to mitigate risk,
including considering offering naloxone when factors that increase risk
for opioid overdose, such as history of overdose, history of substance
use disorder, higher opioid dosages (≥ 50 MME per day), or concurrent
benzodiazepine use, are present.
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clinical reminders
▶

Use immediate-release
opioids when starting.

▶
▶

Start low and go slow.

▶

Do not prescribe ER/LA
opioids for acute pain.

▶

Follow-up and re-evaluate
risk of harm; reduce dose
or taper if needed.

When opioids are needed
for acute pain, prescribe no
more than needed.
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Review prescription drug monitoring program
(PDMP) data.
Clinicians should review the patient’s history of controlled substance
prescriptions using state prescription drug monitoring program (PDMP)
data to determine whether the patient is receiving opioid dosages or
dangerous combinations that put him or her at high risk for overdose.
Clinicians should review PDMP data when starting opioid therapy for
chronic pain and periodically during opioid therapy for chronic pain,
ranging from every prescription to every three months.

Use urine drug testing.
When prescribing opioids for chronic pain, clinicians should use urine drug
testing before starting opioid therapy and consider urine drug testing at
least annually to assess for prescribed medications as well as other
controlled prescription drugs and illicit drugs.

Avoid concurrent opioid and benzodiazepine
prescribing.
Clinicians should avoid prescribing opioid pain medication and
benzodiazepines concurrently whenever possible.

Offer treatment for opioid use disorder.
Clinicians should offer or arrange evidence-based treatment (usually
medication-assisted treatment with buprenorphine or methadone in
combination with behavioral therapies) for patients with opioid use disorder.

6

clinical reminders
▶

Check PDMP for high
dosages and prescriptions
from other providers.

▶

Use urine drug testing
to identify prescribed
substances and
undisclosed use.

▶

Avoid concurrent
benzodiazepine and
opioid prescribing.

▶

Arrange treatment for OUD
if needed.

Chapter Two

Clinical Quality
Improvement (QI)
Opioid Measures
and Protocols

Centers for Disease
Control and Prevention
National Center for Injury
Prevention and Control
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Clinical Quality Improvement
(QI) Opioid Measures and Protocols
This chapter describes the 16 clinical QI opioid measures (Exhibit 1) that align
with the CDC Prescribing Guideline recommendation statements. This chapter
focuses on providing specifics for operationalizing each of the QI measures to
monitor progress in implementing the CDC Prescribing Guideline
recommendations.
Each measure has a table that provides details on calculating the numerator,
denominator, measurement period, and ways to address potential challenges
(Appendix B). In order to help facilitate uptake and use of the QI measures within
clinical workflow, this chapter also describes five steps (Exhibit 2) that a healthcare
system or practice can take.

QI Measures
Based on stakeholder input to support efforts to implement the CDC Prescribing
Guideline, 16 clinical QI opioid measures were developed that align with the 12
Guideline recommendation statements. The measures most commonly draw from EHR
data, and they are for QI purposes to support safe and effective opioid prescribing and
pain management, rather than official performance measurement. Exhibit 1 provides a
list of the QI measures and the applicable Guideline recommendation number.
The QI measures are organized into two categories: new opioid prescriptions and
long-term opioid therapy. The measures are meant to be flexible in terms of how
your practice or system operationalizes or implements them. Your practice or system
should use measures or refine measures to be consistent with your organization’s
internal policies on opioid prescribing and pain management, or reflect state laws or
regulations (e.g., checking PDMP).
Refer to Appendix B for details on the method used to create these measures
Appendix B also includes 16 tables to operationalize each of the 16 QI measures
using EHR data.

▶ A note about effectiveness and time horizon
Several healthcare systems have implemented and evaluated risk reduction (Von
Korff et al., 20161) or QI initiatives (Anderson et al., 20162; Dorflinger et al., 20143)
aimed at improving opioid prescribing, especially for patients on long-term opioid
therapy (LTOT). As part of these initiatives, measures were captured and reported.
Anderson et al.’s (2016) intervention consisted of provider education, electronic
health record (EHR) pain templates, a chronic pain and opioid prescribing policy,
an opioid management dashboard, onsite specialty resources and virtual access
8
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to pain specialists via Project Extension for Community Healthcare Outcomes
(ECHO). They found an increase in provide knowledge and self-rated confidence
from baseline and a statistically significant increase in urine drug screens and
treatment agreements. There were also significant improvements in documentation
of pain, pain treatment and follow-up. A significant increase in referral to behavioral
health, but no significant change in opioid prescribing.
Further, Von Korff et al. (2016) evaluated the Group Health risk reduction initiatives
(in their group practices and contracted care settings) which employed several
implementation approaches including practice tools, patient education materials, a
care plan template and an online calculator for Morphine Milligram Equivalents
(MME), performance measures tracking the development of LTOT care plans in
the EHR, medical staff leader advocacy, expert consultation for physicians, and
financial incentives for completed LTOT care plans. They observed reductions in the
percentage of patients on high MMEs and patients on excess opioid days supplied.
The U.S. Department of Veterans Affairs (VA ) Stepped Care Model has demonstrated
improvements, as well. Dorflinger et al. (2014) found the proportion of patient
receiving high dose opioids decrease over four years, and the use of mitigation
strategies increased. Referrals to physical therapy and chiropractic care and
prescriptions for topical analgesic increased significantly, and referrals to pain
medicine decreased.

1 Von Korff, M., Dublin, S., Walker, R. L., Parchman, M., Shortreed, S. M., Hansen, R. N., & Saunders, K. (2016). The impact of opioid risk reduction initiatives
on high-dose opioid prescribing for patients on chronic opioid therapy. The Journal of Pain, 17(1), 101-110.
2 Anderson, D. R., Zlateva, I., Coman, E. N., Khatri, K., Tian, T., & Kerns, R. D. (2016). Improving pain care through implementation of the Stepped Care Model
at a multisite community health center. Journal of pain research, 9, 1021.
3 Dorflinger, L., Moore, B., Goulet, J., Becker, W., Heapy, A. A., Sellinger, J. J., & Kerns, R. D. (2014). A partnered approach to opioid management, guideline
concordant care and the stepped care model of pain management. Journal of general internal medicine, 29(4), 870-876.
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Exhibit 1: Clinical QI Opioid Measures
QI MEASURE DESCRIPTION
New Opioid Prescription Measures
1. The percentage of patients with a new opioid prescription for an immediate-release opioid.
2. The percentage of patients with a new opioid prescription for chronic pain with documentation that a PDMP was checked
prior to prescribing.
3. The percentage of patients with a new opioid prescription for chronic pain with documentation that a urine drug test
was performed prior to prescribing.
4. The percentage of patients with a follow-up visit within four weeks of starting an opioid for chronic pain.
5. The percentage of patients with a new opioid prescription for acute pain for a three days’ supply or less.

Long-term Opioid Therapy Measures
6. The percentage of patients on long-term opioid therapy who are taking 50 MMEs or more per day.
7. The percentage of patients on long-term opioid therapy who are taking 90 MMEs or more per day.
8. The percentage of patients on long-term opioid therapy who received a prescription for a benzodiazepine.
9. The percentage of patients on long-term opioid therapy who had a follow-up visit at least quarterly.
10. The percentage of patients on long-term opioid therapy who had at least quarterly pain and functional assessments.
11. The percentage of patients on long-term opioid therapy who had documentation that a PDMP was checked
at least quarterly.
12. The percentage of patients on long-term opioid therapy who the clinician counseled on the risks and benefits
of opioids at least annually.
13. The percentage of patients on long-term opioid therapy with documentation that a urine drug test was
performed at least annually.
14. The percentage of patients with chronic pain who had at least one referral or visit for nonpharmacologic therapy
as a treatment for pain.
15. The percentage of patients on long-term opioid therapy who were counseled on the purpose and use of naloxone,
and either prescribed or referred to obtain naloxone.
16. The percentage of patients with an opioid use disorder (OUD) who were referred to or prescribed medicationassisted treatment (MAT).
Click on each measure to see details on operationalizing the measure using EHR data.

10
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QI Implementation Steps
To encourage the use of the QI measures, five Implementation Steps are outlined.
These are steps providers in a practice or healthcare system can take to ensure
buy-in, receptivity, and ultimately, use of the measures. Following the description
of each step, there are self-assessment questions to facilitate your implementation
team’s reflection on your progress. The complete self-assessment questionnaire
is available in Appendix C. Throughout this section, there are quotes from staff
in other systems who have implemented similar changes that illustrate the
importance of such changes.

Exhibit 2: Five Steps for Implementing an Opioid QI Effort
in a Healthcare System or Practice
Step 1: Obtain Leadership Support and Identify a Champion(s)

•
•
•
•

Obtain leadership support as a critical first step
Identify a champion(s) to drive the change process
Form a change team (if appropriate) or at least engage key staff
Obtain needed resources and determine readiness

Step 2: Assess Current Approach to Opioids and Identify Areas for Improvement

•
•
•
•
•

Assess current policies and practices
Complete the self-assessment questionnaire
Collect data on your patient population and opioid therapy
Determine access to specialists and other resources
Identify areas to improve upon

Step 3: Select and Prioritize Guideline Recommendations to Implement

•
•

Determine which Guideline recommendations to implement
Prioritize what will be implemented

Step 4: Define System Goals

•

Set measurable goals

Step 5: Develop a Plan, Implement, and Monitor Progress

•
•
•

Develop a plan for implementing selected Guideline recommendations
Implement the changes
Monitor progress using QI measures and other data

11
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STEP 1

Obtain Leadership Support
and Identify a Champion(s)
Obtain leadership support as a critical first step
Obtaining leadership support is a critical first step to pursuing any change
initiative in a practice or system. You might obtain support by identifying
key drivers for the change effort, such as aligning the effort with the mission
of the practice, highlighting any effect opioid prescribing is having on staff
satisfaction, or making financial arguments for the changes. Keeping leadership
involved and informed throughout implementation is essential.

Identify a champion(s) to drive the change process
Champions support and drive the change process, even in the face of
organizational stagnancy, indifference, or active resistance. Effective champions in
primary care settings are likely to possess leadership qualities even if they are not
in leadership positions, are good models for others, and are skilled in motivating
others to work as a team. They typically have strong relationships with leadership,
which is an important resource when changes in established policies, approach,
and workflow are needed. A champion should be someone on-site where the
changes are taking place.

Form a change team or at least engage key staff
If your practice or system has the resources and is able to create a change
team, they can be responsible for the next steps, including implementing and
monitoring the changes. The team should be interdisciplinary and should
consist of leaders and staff. It is important to have clear roles for the champion
and other change team members. Ideally, the team will include a range of
roles, all of which will be involved in the change effort (e.g., medical directors,
clinicians, nurses, medical assistants, pharmacists, behaviorists, clinical and/or
front office staff managers, case workers). Consider representation from other
key areas, such as IT, as many of the practice recommendations involve creating
workflows within an EHR and pulling reports for clinical QI measures.

Obtain needed resources and determine readiness
Leadership should provide the necessary resources, both in terms of staff time
and budget. Leadership should free up the champion’s time for implementing
the changes, since trying to change the practice in addition to carrying his/her
normal load of patients or primary responsibilities is unlikely to produce positive
results. Leadership should ensure the champion has the authority needed to make
changes and hold the team accountable.
Also consider the readiness of your practice to implement the changes needed and
potential barriers to implementation, such as competing demands, forthcoming
EHR changes, and financial incentives (or lack thereof ). Additionally, your practice
should be cautious about tackling too much at once. Aim for small wins that can be
built upon and which will encourage rather than discourage further engagement.
12

field notes
“If leadership does not
think it is a priority, then the
clinicians won’t be given
the resources they need.
They also need to be very
involved so that they can
hold clinicians accountable.”
“Once a practice realized
they were the outliers in
the community around
not having patients
do UDT and that it
was one of the CDC
Prescribing Guideline
recommendations,
they found a champion
medical assistant (MA)
to lead the charge and
within a month had
developed workflows
for regular UDT for
patients on long-term
opioid therapy.”
“I feel like [our practice]
made more progress
because of [our champion’s]
unrelenting focus to engage
the medical staff. Because
of their engagement, they
were willing to try things.”
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▶ Self-assessment for Step 1

self-assess

Step 1: Obtain Leadership Support and Identify a Champion(s)
1. Obtain leadership support

1

2

3

4

5

2. Identify a champion(s) to drive the
change process

1

2

3

4

5

3. Identify and engage a change team
or key staff

1

2

3

4

5

4. Allocate resources to support
champion and/or change team

1

2

3

4

5

5. Consider the readiness of your system
and potential barriers to implementing
changes

1

2

3

4

5

Source: The self-assessment questionnaire was developed as part of a research project on
team-based opioid management in rural clinics led by Dr. Michael Parchman (parchman.m@
ghc.org), Director, MacColl Center for Innovation, Kaiser Permanente Washington Health
Research Institute and funded by the U.S. DHHS AHRQ grant #R18HS023750. See: https://www.
improvingopioidcare.org/6-building-blocks/.

STEP 2

Assess Current Approach to Opioids
and Identify Areas for Improvement
Assess current policies and practices
Begin by assessing your current policies and practices for opioid prescribing.
Are your policies well documented? Do they cover all the key aspects of opioid
use? How well are the policies communicated to prescribers and their team? To
more systematically assess current practices, your system could survey or interview
clinicians about gaps in care or issues they encounter, or even ask questions at a
staff meeting. You might also convene clinicians to discuss and reflect on key
questions (e.g., “Do our current policies adequately address the issues that come
up with patients on opioids?”). Finally, sharing patient stories can illuminate the
challenges with opioids and motivate staff for a QI effort.

Complete the self-assessment questionnaire
Complete the self-assessment questionnaire (Appendix C) to determine your
system’s current status on steps in the QI effort and with specific Guideline
recommendations (Step 3). Ideally, the assessment should be completed as a team
(i.e., implementation team including leadership) or at least by multiple individuals
from across the healthcare system or practices that are involved in prescribing
opioids. Additionally, it is important to include different members of the care team,
since perspectives might differ depending on one’s position. The self-assessment is
also a useful tool for getting team members on the same page.
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These are the selfassessment questions
to facilitate your
implementation team’s
reflection on your progress.
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Collect data on your patient population and
opioid therapy
Some basic patient population information is needed to help guide the QI
implementation. How many patients are on long-term opioid therapy? How
many patients are prescribed opioids? While it is not necessary at this stage to
be exhaustive, you will want to collect sufficient data to help you decide on your
system goals (Step 4). You might consider pulling the denominators for the QI
measures (Step 5). For this QI initiative, your EHR will be an essential tool. As
mentioned in Step 1, it is a good idea to include the EHR IT staff as members of
your implementation team.

Determine access to specialists and other resources

field notes
“[Registry Manager] did
a list of patients for each
clinician and calculated
all of their morphine
milligram equivalents
(MMEs). She showed it to
them, and the clinicians
were very competitive.”

Determine which specialists and other resources your practice does or does not
have available within the system or in the community. This may include access to
laboratory services, behavioral health specialists, pain management specialists,
addiction specialists, interventionists, buprenorphine waivered clinicians, and the
development of a registry for easy referral to these types of specialists and services.

Identify areas to improve upon
Based on your assessment results, you will likely identify areas for improvement in
your policies, prescribing practices, workflows, and resources needed to support
care of patients with chronic pain or on long-term opioid therapy. Additionally, the
results of your assessment may highlight to clinicians and leaders alike the extent
of unsafe practices with opioids (e.g., high dosages) in your system.

▶ Self-assessment for Step 2
Step 2: Assess Current Approach to Opioids and Identify Areas for Improvement
6. Assess current policies and practices

1

2

3

4

5

7. Have key staff complete this selfassessment questionnaire

1

2

3

4

5

8. Collect data on your patient population
on opioid therapy

1

2

3

4

5

9. Determine access to specialists and
other needed resources

1

2

3

4

5

10. Identify areas of practice in need of
improvement

1

2

3

4

5

Source: https://www.improvingopioidcare.org/6-building-blocks/
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self-assess
Complete these selfassessment questions
to facilitate your
implementation team’s
reflection on your progress.
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STEP 3

Select and Prioritize Guideline
Recommendations to Implement
Determine which Guideline recommendations
to implement
Once your system understands your areas to improve upon (Step 2) and
completes the self-assessment questionnaire (Appendix C), your system
should decide which CDC Prescribing Guideline recommendations to pursue
to address your needs and meet your goals. Each of the CDC Prescribing
Guideline recommendations is provided below along with considerations
for implementation based on the experiences of other systems and practices
implementing these changes.
Exhibit 3 provides each of the 12 CDC Prescribing Guideline recommendations
along with considerations for implementation based on other systems’ and
practices’ experiences and the lessons they learned.

field notes
"We realized that if we
added up all the time our
clinic spent with patients
who were not being
managed effectively
and safely on long-term
opioid therapy (e.g., front
office fielding phone calls,
MA’s calling patient back
and 'getting the story,'
setting up contracts with
patients, etc.), it was less
than the amount of time
it took us to systematically develop workflows and
follow them.”

Exhibit 3: Considerations for Implementation (Organized by Recommendation Statement)
CONSIDERATIONS FOR IMPLEMENTATION

CDC GUIDELINE RECOMMENDATION STATEMENT
1. Opioids should not be the first-line therapy.

• Access can be a big issue; determine the nonpharmacologic therapies
your practice already can access, and which ones can be accessed
in the community. For example, while a practice may not have
integrated behavioral health specialists, there are often community
therapists and psychologists who can co-treat.
• Before referring to patients to specialists, indentify any challenges or
barriers to receiving services due to insurance coverage.
• Determine if low-cost options for nonpharmacologic therapies, such
as behavioral health specialists, are available in community.
• Consider focusing on chronic pain conditions that can benefit from
a specific nonopioid or nonpharmacologic therapy and start there,
such as low back pain patients being referred to physical therapy or
given exercise/stretches handouts by clinicians.

2. Establish goals for pain and function.

• Discuss with your clinicians how treatment goals are currently
captured and established in collaboration with patients. For example,
is there a specific place within the EHR to capture treatment goals
and record each visit?
• Use the PEG to assess pain and functional improvement and teach
clinicians how to use the results with patients.

15
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CONSIDERATIONS FOR IMPLEMENTATION

CDC GUIDELINE RECOMMENDATION STATEMENT
3. Discuss risks and benefits.

• Several clinics used their treatment agreements to drive home the
risk of taking opioids long term. These agreements should be used to
facilitate conversations, not solely for documentation purposes.
• Make sure patients understand components of the treatment
agreement and what is necessary for them to continue getting
their medication(s).
• If patients choose to self-taper, then clinicians should collaborate
with the patient on a tapering plan.
• Establish a process to document clearly that this has been done,
either in agreement or in the EHR. This is critical for risk management.

4. Use immediate-release opioids
when starting.

• Develop a policy to improve consistency across clinicians.

5. Use the lowest effective dose.

• Develop a policy on threshold dosages.

• Provide education or training to clinicians.

• Incorporate an alert in the e-prescribing system for clinicians to justify
high dosages, when rendered appropriate for a specific patient.
• Use a “dashboard” to show clinicians’ current percentages or number
of patients on high dosages; spur peer competition.
• Consider “case reviews” with higher MME patients so providers are held
accountable and also given implementation strategies by the team.
• Consider a practice-wide CME or training event detailing the
CDC Prescribing Guideline with explanation and education on
monitoring and protecting against unintended consequences (e.g.,
discontinuation, too-rapid tapering without true patient consent,
discharge from practice).
6. Prescribe short durations for acute pain.

• Develop a policy for new opioid prescriptions for acute pain.
• Keep abreast of relevant policies and changes in policy and
regulation at the state level. Consider doing risk assessment
with patients asking for refills of opioid prescriptions that are
for acute pain.

7. Evaluate benefits and harms frequently.

• Develop workflow to ensure patients are scheduled for a follow-up
visit before leaving with a new opioid prescription for long-term
opioid therapy.
• Establish a policy and train staff to refuse authorization of a first refill
of a new opioid prescription until the patient has been in for a followup visit.
• Develop a policy that new prescriptions for opioids will be written
with no refills until after the patient has had a follow-up visit.
• Provide a practice-wide training event detailing the CDC
Prescribing Guideline with explanation and education on
monitoring and protecting against unintended consequences
(e.g., discontinuation, too-rapid tapering without true patient
consent, discharge from practice).
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CONSIDERATIONS FOR IMPLEMENTATION

CDC GUIDELINE RECOMMENDATION STATEMENT
8. Use strategies to mitigate risk.

• Develop a policy of prescribing naloxone for high-risk patients
on long-term opioids.
• Train clinicians and staff on use of naloxone.
• Consider using pharmacist, nurse, nurse practitioner, medical
assistant, or physician assistant to train patients and their loved
ones on when and how to use naloxone.
• Identify behavioral health specialists for collaboration,
communication, and referral.
• Determine if there are any challenges or barriers to receiving
nonpharmacologic therapies due to insurance coverage, and
identify any low-cost options for nonpharmacologic therapies,
such as behavioral health specialists, available in community.

9. Review PDMP data.

• Develop a policy on the frequency of checking the PDMP.
• Keep abreast of relevant policies and changes in policy and
regulation at the state level.
• Consider using pharmacist, nurse, nurse practitioner, medical
assistant or physician assistant to check PDMP in states that allow
delegate access.

10. Use urine drug testing.

• Determine the feasibility for your practice setting to implement
urine drug testing.
• Determine the level of verification needed for your practice setting
and implement an appropriate process; some clinics may choose
higher levels of verification, such as using temperature sensitive
UDT or direct observation of urine sample collection.
• Provide a quick link from the EHR for the specific UDT.

11. Avoid concurrent opioid and benzodiazepine
prescribing.

• Use clinical decision support (CDS) reminders to ensure
clinicians avoid co-prescribing, whenever possible.
• Facilitate clinicians checking the PDMP for prescriptions of
benzodiazepines by integrating the PDMP into the EHR, as feasible.
• Track and monitor co-prescribing and provide clinicians
with feedback.
• Clinicians should collaborate on a tapering plan with existing
patients who are receiving benzodiazepines.
• Involve the mental health professionals managing the patient
to discuss the patient’s needs, prioritize patient goals, weigh
risks of concurrent benzodiazepine and opioid exposure, and
coordinate care.

12. Offer treatment for opioid use disorder.

• Identify available clinicians to prescribe MAT for patient referrals.
• Help clinicians in your practice obtain buprenorphine waivers
(see: https://www.samhsa.gov/medication-assisted-treatment/
buprenorphine-waiver-management).
• Provide training on diagnosing OUD.

17
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Prioritize what will be implemented
Once you have decided what to implement, consider what your system might
prioritize if there are too many changes to undertake all at once and be successful.
You might prioritize the changes that are most needed based on findings from
your assessment (Step 2). Or you might consider not selecting the hardest
changes first but go for an early win to build momentum before progressing to a
more involved change in practice.

▶ Self-assessment for Step 3
Step 3: Progress Towards Implementation of Guideline Recommendations
11. Consider practice-level changes

1

2

3

4

5

12. Decide which Guideline
recommendations to implement

1

2

3

4

5

13. Prioritize what will be implemented

1

2

3

4

5

self-assess
Complete these selfassessment questions
to facilitate your
implementation team’s
reflection on your progress.

Source: https://www.improvingopioidcare.org/6-building-blocks/

STEP 4

Define System Goals
Once you have assessed your current approach and identified areas for
improvement, the next step is to define the specific goals your practice
aims to achieve. The change team should determine the goals with input
from key stakeholders (e.g., clinicians, leadership).
The following are some examples of goals:

•
•
•
•

Policies on opioid prescribing will be reviewed and revised within X months.
At least two clinicians will become buprenorphine-waivered (or have a list
of community providers available who are waivered) within X months.
Number of patients prescribed opioids and benzodiazepines concurrently
will be reduced by X% within Y months.
Number of patients prescribed opioids at > 50 MMEs will be reduced by
X% within Y months.

▶ Self-assessment for Step 4
Step 4: Define System Goals
14. Set measurable goals

1

2

3

Source: https://www.improvingopioidcare.org/6-building-blocks/

18

4

5

self-assess
Complete these selfassessment questions
to facilitate your
implementation team’s
reflection on your progress.
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STEP 5

Develop a Plan, Implement, and
Monitor Progress
Develop a plan for implementing selected
Guideline recommendations
Once your practice has defined your goals and selected the relevant recommendations,
the next step is to develop an implementation plan—ideally focusing on initial
implementation, then go through a Plan-Do-Study-Act (PSDA) cycle (i.e., tool for
improving QI). If your practice has an established, structured improvement approach,
you should use that approach.
Develop a plan that outlines the following:

•
•
•
•

Who will spearhead changes (Step 1)?
What are the areas for your system to improve upon (Step 2)?
What are the CDC Prescribing Guideline recommendations to be
implemented (Step 3)?
When and how will the necessary components be implemented (Step 3)?
• EHR changes?
• Changes in workflow?
• New tasks for specific staff?
• Communication to staff?

•
•

• Training of staff?
What are the goals (Step 4)?
How will progress be monitored (Step 5)?

Implement the changes
Difficulties in implementing practice changes can be minimized by thoughtful
planning and by understanding in advance the concerns of stakeholders whose
interests and work will be affected.
(See Toolkit Part F for a list of potential challenges or barriers to implementing
long-term opioid management strategies and potential solutions.)

Monitor progress using QI measures and other data
An essential element of any practice improvement effort is monitoring progress
towards the goals outlined. Your system should monitor progress using existing
data and approaches outlined in Step 2. For example, complete the self-assessment
questionnaire (Appendix C) to assess your practice before you implement changes
and periodically reflect on progress on each step and selected change. Your system
should select the QI measures to assess your system’s baseline and monitor progress
on a quarterly basis on any of the 16 measures that align to the CDC Prescribing
Guideline recommendations your system has decided to pursue. See Appendix B
to operationalize each measure.
19
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The results of monitoring should be reported on a regular basis by the champion or
change team to leadership and other stakeholders. These results can be discussed
with the change team to identify any mid-course adjustments that may be needed.

self-assess

▶ Self-assessment for Step 5
Step 5: Develop a Plan, Implement, and Monitor Progress
15. Develop a plan for implementing
selected Guideline recommendations

1

2

3

4

5

16. Implement selected Guideline
recommendations

1

2

3

4

5

17. Monitor progress using the QI
measures and other data

1

2

3

4

5

Source: https://www.improvingopioidcare.org/6-building-blocks/
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Complete these selfassessment questions
to facilitate your
implementation team’s
reflection on your progress.

Chapter Three

Practice-level Strategies
for Care Coordination
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Practice-level Strategies for
Care Coordiation
Improving management and coordination of long-term opioid therapy requires
not only a refined approach to the clinical care of patients but also strategies
that can be deployed at the practice- and system-level of care delivery.
These strategies include establishing or revising internal opioid policies, developing
registries and using panel management, employing team-based approaches, and
effectively using technology, each of which is briefly described below. All of these
strategies can be used together to have a comprehensive approach. Throughout this
chapter, tips for specific strategies are provided that are based on the experience
of a healthcare system aimed to implement this plan into its primary care practices.
Toolkit Part A provides links to examples of comprehensive management and
coordination approaches.
STRATEGY

Use an Interdisciplinary
Team-based Approach

tip

▶ Use an interdisciplinary, team-based approach to managing and

coordinating long-term opioid therapy to the extent possible (e.g., have
a medical assistant manage opioid refill requests or schedule UDTs).

▶ Determine which specialists are available within the practice or need to

be identified for referrals (e.g., psychologists, psychiatrists, clinical
pharmacists, addiction specialists, social workers, rehabilitation medicine,
physical therapists, chiropractors, anesthesiologists, occupational
therapists, and acupuncturists or other providers of complementary
and alternative medicine).

▶ Determine if patients with an opioid use disorder have sufficient access to

providers of MAT. If availability is inadequate, strongly consider having one
or more providers seek a waiver to provide buprenorphine to these patients.
(For waivers, see http://www.samhsa.gov/medication-assisted-treatment/
buprenorphine-waiver-management.)

▶ If needed, use telemedicine consultations (e.g., Project Extension for

Community Healthcare Outcomes [ECHO]) to obtain advice from pain
specialists via videoconference. (See Toolkit Part D for more details.)

▶ Identify workflow modifications that may be necessary to support
selected strategies.
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Managing long-term
opioid therapy
successfully is not
something one
provider can easily
manage alone.
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STRATEGY

Establish Opioid Policies
and Standards
▶ Develop and implement policies or standards to promote consistency
in long-term opioid therapy management and coordination.

Practice-wide policies and standards both support providers in making clinical
decisions that protect patient safety (e.g., decisions to avoid inappropriate dose
escalation)1 and promote consistency in long-term opioid therapy management
and coordination. (See Toolkit Part B for a list of potential policies.) Examples of
policies include:

•

All patients receiving long-term opioid therapy must sign or review an
opioid treatment agreement and informed-consent form;

•

All patients receiving long-term opioid therapy must notify the practice
three or four days prior to receiving an opioid refill; and

•

Providers check the PDMP data periodically for patients receiving longterm opioid therapy, no less often than every three months. PDMPs are
state-based databases that collect information on controlled prescription
drugs dispensed by pharmacies in most states and, in some select states,
by dispensing physicians as well.

The following are policies the practice could consider developing, establishing, or
updating. Internal policies should allow for some flexibility and discretion to be
consistent with the spirit of the CDC Prescribing Guideline. Clinical decisionmaking should be based on a relationship between the clinician and patient, and
an understanding of the patient’s clinical situation, functioning, and life context.
Clinicians should consider the circumstances and unique needs of each patient
when providing care, and policies should allow for this as well.

Standard treatment agreement for all
providers to use
Treatment agreements are useful for defining the responsibilities of the patient
and provider, creating a structure to guide and evaluate opioid use, reducing opioid
misuse, enhancing adherence to opioid therapy as prescribed, reducing providers’
legal risk, and improving practice efficiency.2 It is important to emphasize the
treatment agreement is not just about getting a form signed but is a tool for
facilitating a conversation between the provider and patient.

▶ Develop treatment agreements that include the following information:
• Potential risks and benefits of opioid therapy;
• Clinical guidance that opioids may not improve pain or function;
• Prescribing and/or practice policies (e.g., dose limits, only one prescriber,
•

only one pharmacy, refill policy);
Methods of monitoring opioid use (e.g., urine drug tests, periodic visits,
checking PDMPs); and

•

Behaviors expected of the patient.

1 Kilaru AS, Gadsden SM, Perrone J, Paciotti B, Barg FK, Meisel ZF. How do physicians adopt and apply opioid prescription guidelines in the emergency
department? A qualitative study. Annals of emergency medicine. 2014;64(5):482-489. e481.
2 Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. The journal of pain: official
journal of the American Pain Society. 2009;10(2):113-130.
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tip
Terminology is
important
Treatment agreements are
sometimes called “treatment
contracts.” Use of the term
“contract” may have legal
and punitive connotations to
some, suggesting mistrust,
whereas the use of “agreement”
implies that parties have
reached a mutually acceptable
arrangement. When developing
a treatment agreement,
practices should be cautious
with the use of adversarial
or intimidating language. In
discussing the agreement,
emphasis should be placed
on how its provisions are
intended to protect patient
safety. This may enable the
patient and physician to find
common ground on potentially
contentious issues. Ensuring
patient safety provides a
rationale for erring on the side
of caution when considering
opioids for chronic pain.
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Examples of treatment agreements are provided in Toolkit Part C. More guidance on
how the provider can address this with individual patients is provided in Chapter 1.

Policy on the threshold dosage levels for
the patient population
Research has found that patients who receive high MME dosages have significantly
increased risks of overdose compared with patients receiving low dosages (Exhibit
3).3-6 (Even at low dosages, opioids present risk of overdose.) Establishing a practicewide policy on dosage levels may assist prescribers in making evidence-based
decisions and minimizing risks of adverse outcomes.

▶ Consider implementing CDC’s guidance on dosing:7
• Use caution when prescribing opioids at any dosage and prescribe the
lowest effective dose.

•

•

Use extra precautions when increasing to ≥ 50 MME per day, such as:

-

Monitor and assess pain and function more frequently.

-

Consider offering naloxone.

Discuss reducing dose or tapering and discontinuing opioids if
benefits do not outweigh harms.

Avoid or carefully justify increasing dosage to ≥ 90 MME per day.

▶ Patients already at high levels may be willing to try reducing the dosage.
The practice should consider advising prescribers, as a matter of policy, to discuss
this with their patients who are taking more than 50 MME per day. (See Chapter 1
for discussions of opioid dosage for individual patients.)

•

Providers are encouraged to read the full CDC Prescribing Guideline for
additional information on improving patient outcomes, such as reduced
pain and improved function. Within the CDC Prescribing Guideline there are
recommendations that are tailored to specific populations (e.g., pregnant
women, older adults) and additional guidance on opioid therapy and
tapering. The additional details provided within the rationale statements,
will assist providers with improving the care and treatment of patients living
with chronic pain. Patients should receive appropriate pain treatment based
on a careful consideration of the benefits and risks of treatment options.
In treating chronic pain, providers should continue to use their clinical
judgment and base their treatment on what they know about their patients.
Clinicians should empathically review benefits and risks of continued highdosage opioid therapy and should offer to work with the patient to taper
opioids to safer dosages. For patients who agree to taper opioids to lower
dosages, clinicians should collaborate with the patient on a tapering plan.

3 Dunn KM, Saunders KW, Rutter CM, et al. Opioid Prescriptions for Chronic Pain and Overdose. Annals of internal medicine. 2010;152(2):85.
4 Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315-1321.
5 Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of Internal
Medicine. 2011;171(7):686-691.
6 Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med.
2014;15(11):1911-1929.
7 Centers for Disease Control and Prevention. Calculating total daily dose for opioids for safer dosage. https://www.cdc.gov/drugoverdose/pdf/calculating_total_
daily_dose-a.pdf
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tip
Treatment
agreement
Determine where within the
EHR the treatment agreement
should be saved and how it
should be labeled to ensure
easy searching and retrieval
for a provider to determine
if a patient has a treatment
agreement and when it was
last reviewed and signed.
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Prescription refill or renewal policy
▶ Include any prescription renewal/refill policies in the treatment agreement.
Examples of prescription refill or renewal policies are: limiting supply to 28 days;
not allowing early refills; and requiring three business days advance notice for refills.

Policy for frequency of monitoring patients
on long-term opioid therapy
Because most risk-assessment instruments are unable to predict future behavior
with a high degree of accuracy,8 a universal precautions approach to all patients
on long-term opioid therapy is appropriate. That is, opioid use by all patients on
long-term therapy should be monitored periodically. The frequency and intensity
of monitoring individual patients, however, should be greater for those who are
taking high dosages of opioids, who have other conditions that put them at higher
risk (e.g., hepatic deficiency or sleep disordered breathing), whose behavior shows
them to be at higher risk (e.g., frequent requests for early refills), or who report
indicators of OUD when asked. How these decisions are made for individual
patients is discussed in Chapter 1.

▶ Establish policies for how monitoring should be calibrated to perceived risk.

Policy for frequency of urine drug testing
UDTs are useful for determining if patients are taking their opioid medications as
prescribed or are using other licit or illicit substances. UDTs should be supplemented
by careful, non-judgmental interviewing by clinicians in the practice and patient
observation to identify indicators of OUD or potentially hazardous opioid misuse.
There are two main types of UDT—immunoassay drug-testing conducted at
a laboratory or at the point of care in a provider’s office, and laboratory-based
chromatography/mass spectrometry. (See Exhibit 4 for a description of the main
differences in these two types of tests and further information regarding
conducting UDT as part of monitoring and risk management.

8 Chou R, Deyo R, Devine B, Hansen R, Sullivan S, Jarvik Jea. The Effectiveness and Risks of Long-term Opioid Treatment of Chronic Pain. Evidence Report/
Technology Assessment No. 218. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
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tip
Urine drug
testing
It can be helpful to determine
the specific, urine drug
test that should be used to
capture all of the relevant licit
and illicit drugs. Make this
specific test readily apparent
within the EHR order system
for providers to choose.
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Exhibit 4: Differences in Types of Urine Drug Tests
IMMUNOASSAY
Less expensive, fast, easy to use.

GAS CHROMATOGRAPHY, MASS SPECTROMETRY
More expensive, labor intensive.

Most frequently used technique in all settings, including hospital labs. Requires advanced laboratory services.
Used commonly as screening test.

Used primarily to confirm positive immunoassay result.

Engineered antibodies bind to drug metabolites.

Measures drugs and drug metabolites directly.

Qualitative testing—positive or negative only.

Quantitative testing.

Screens for presence of drugs or a panel of drugs: amphetamine,
marijuana, PCP, cocaine, natural opiates (morphine/codeine/thebaine
but without differentiation). Heroin is metabolized to morphine and
can therefore be detected.

Identifies specific drugs and their metabolites.

Does not differentiate various natural opiates.

Differentiates all opioids.

Typically misses semi-synthetic and synthetic opioids.

More accurate for semi-synthetic and synthetic opioids—methadone,
propoxyphene, fentanyl, meperidine, hydrocodone, oxycodone,
hydromorphone, oxymorphone, buprenorphine, heroin.

Often has high cut-off levels, giving false negative results.

Very sensitive, detects low levels of drug, minimizes false negatives.

Will show false positives: poppy seeds, quinolone antibiotics,
over-the-counter medications.

Very specific, less cross-reactivity, minimizes false positives.

Source: Adapted from “Urine Drug Testing in the Management of Chronic Pain,”
at https://www.drugabuse.gov/sites/default/files/files/UrineDrugTesting.pdf

▶ Establish a policy specifying how often UDTs should be given to patients
at different levels of perceived risk.

The practice should also consider whether tests are to be done at random or on
a particular schedule. The cost of testing should be factored into this decision. As
discussed in Chapter 1, the frequency of testing may be increased if results are
inappropriate or unexplained, due to risk level, or following each dosage increase.

Policies and procedures for checking the
prescription drug monitoring program
Periodic checks of the PDMP provide a direct means of monitoring the patient’s use of
multiple prescribers or multiple pharmacies as well as the frequency and amounts of
controlled substances prescribed and purchased.

▶ Providers in the practice should register to access the PDMP data.
▶ Check PDMP data frequently.
▶ Consider efficient procedures for integrating PDMP checks into the

practice (e.g., delegating a medical assistant to obtain the patient’s
prescription history).

▶ Establish procedures for providers or their delegates, if applicable, to

obtain PDMP data on their long-term opioid therapy patients periodically,
in accord with the practice’s policy.

9 Anderson D, Zlateva I, Khatri K, Ciaburri N. Using health information technology to improve adherence to opioid prescribing guidelines in primary care.
The Clinical Journal of Pain. 2014.
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tip
PDMP
Create a single sign-on link to
the PDMP to facilitate checking
the PDMP into the clinicial
workflow. Ensure all providers
are registered with the PDMP,
and if allowable, utilize
delegates to access the PDMP
data and give that to providers
before a clinical encounter or
refill authorization.
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In most states, providers may delegate their authority to access the PDMP data,
although the procedures for doing so vary by state. Some state laws allow one
provider in a practice to register for access and delegate to an assistant who can
obtain PDMP information for all providers in the group. Information about state
PDMPs and associated regulations for use is available at The National Alliance
for Model State Drug Laws (http://www.namsdl.org/prescription-monitoring
programs.cfm).
STRATEGY

Use EHR Data to Develop Patient
Registries and Track QI Measures
EHRs are critical sources of information for managing and monitoring the extent
to which the long-term opioid therapy procedures are being implemented by
the care teams.

▶ Develop a clinical dashboard, so providers can see how their patients
and their implementation of specific clinical practices compare to
their colleagues.

tip
EHRs
Ensure that any EHR templates
and fields are incorporated
into the clinical workflow of
providers and auto-populated
to the extent possible to
facilitate use.

▶ Use dashboards to measure the extent to which providers adhere to
the practice’s policies or for monitoring improvements.9

▶ Implement QI measures using EHR data (as described in Chapter 2).
Registries are used to identify patients to target for specific interventions—in this
case, for management and coordination of long-term opioid therapy. They are also
used to generate quality measures and to monitor progress at the provider and
practice levels. Consider:

▶ A registry of patients on long-term opioid therapy to measure progress

toward practice goals and to support providers in managing their panel
of patients on long-term opioid therapy.

▶ A registry to identify patients who may be transitioning from short-term

use for acute pain to long-term opioid use for chronic pain and may need
to be evaluated prior to making the decision to use prescription opioids
long term.

▶ A written procedure that specifies who is responsible for entering the

data and when, who manages the data, and when and how reports are
produced and distributed to providers and to the leadership team.
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tip
Registry
It is important to not just
develop a registry as data for
management or monitoring
but also to feed back the
information to providers
to motivate prescribing
behavior changes and ideally
pair report results with
accountability or incentives.
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Methods Used to Develop Clinical QI Opioid Measures
The clinical QI opioid measures were developed to align with each of the 12 recommendation
statements contained in the CDC Guideline for Prescribing Opioids for Chronic Pain. The measures
were refined based on multiple stages of external stakeholder feedback conducted under contract
to Abt Associates (Contract No. 200-2016-F-92356.)
Individual input was sought from stakeholders external to CDC to develop the QI measures. Stakeholders
had either clinical or research expertise in the topic of opioids, quality improvement, or direct experience
implementing QI for opioids. Stakeholders represented physicians, nurses, physician assistants, researchers,
IT specialists, and healthcare system quality managers.
The stakeholders provided individual input via a survey, interviews, and discussion. The stakeholders evaluated
each measure on six dimensions (importance, face-validity, timeliness, acceptability, usability, feasibility) and
provided an overall rating using a five-point Likert scale. They then selected the ten measures most needed
for improving opioid safety, and of those, the five easiest to produce. Responses on each dimension were
averaged; other data (i.e., open-ended survey items, interviews/ discussion) were qualitatively synthesized.
The list of 16 QI measures reflects input from this stakeholder engagement process.

Key definitions for operationalizing the QI measures
These definitions of key terms may be helpful to providers in a practice or healthcare system that are taking steps
to integrate these measures into EHRs:

•

•
•
•
•
•

Data sources: Measures can be based on electronic health record (EHR) data, e-prescribing data,
chart reviews, or other health systems/practice data. The data source for some measures may require
systems to create a structured field, whether via a note template, checkbox, registry, or other means in
which clinicians or staff can attest to having completed a task that could otherwise not be captured. As
data and systems evolve, there may be opportunities to use additional data from these systems (e.g.,
Prescription Drug Monitoring Program, e-prescribing).
Denominator exclusions: active cancer, palliative, and end-of-life care (define by ICD-10 codes)
Long-term opioid therapy: ≥ 60 days’ supply of opioids within a quarter. (Note: If determining days is
too difficult, an alternative is to define it as at least two consecutive opioid prescriptions in a quarter.)
New opioid prescription: prescribed an opioid with no other opioid prescription in the previous 45 days.
Population: outpatient setting and patients 18 years or older. While these Guideline recommendations
also primarily focus on patients with chronic pain, we do not always encourage chronic pain to be the
denominator given the complexities of capturing those ICD-10 codes.
Time periods:

- The measurement period is the time period within which the clinical activity specified (numerator)
should take place (e.g., one year, 90 days, one week, or any period of time).

- The frequency of measurement is the frequency with which the measures will be produced by a

healthcare system or practice (e.g., quarterly). Your practice should determine the frequency that fits
its needs or aligns with its other QI efforts. Recommend 90-day/quarterly intervals.
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Methods Used to Develop Practice-level
Strategies for Care Coordination
The three practice-level strategies were developed to provide practical guidance for specific strategies
to improve the coordination of long-term opioid therapy at the healthcare system and practice level.
This project was completed under contract to Abt Associates (Contract No. 200-2011-42071.)
The practice level strategies featured in Chapter 3 were developed by synthesizing elements from (1) the CDC
Prescribing Guideline; (2) reliance on care coordination plans developed by Kaiser Permanente Washington
(formally Group Health) in Washington State and the VA; (3) findings of relevant scientific studies of opioid
management, treatment, and associated risks; (4) informational calls with representatives of healthcare systems
that have implemented opioid prescribing guidelines, policies, and/or practices; and (5) the results from a
healthcare system that assessed the feasibility of implementing the practices recommended in the document
also informed development of this plan.

The practice level strategies for care coordination that were
developed based on the above sources are:
▶ Use an interdisciplinary team-based approach
• Using a team-based approach across multiple disciplines and specialties improves the
management and coordination of care.

▶ Establish opioid policies and standards
• Developing and implementing practice-wide policies or standards to support and encourage
consistent long-term opioid therapy management and coordination.

▶ Use EHR data to develop patient registries and track QI measures
• EHRs are critical sources of information for managing and monitoring implementation by care teams

and registries are useful to identify patients to target for specific interventions and care coordination.
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Short-term Opioid Therapy Measures
Measure 1: Use Immediate-release Opioids

MEASURE 1: USE IMMEDIATE-RELEASE OPIOIDS

CDC Prescribing Guideline
Recommendation 4

When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids
instead of extended-release/long-acting (ER/LA) opioids.

Description

The percentage of patients with a new opioid prescription for an immediate-release opioid.

Numerator

The number of patients with a prescription for an immediate-release opioid only, and no concurrent
prescription for an extended-release or long-acting opioid.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older prescribed an opioid
who had no opioid prescription in the previous 45 days.

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care, and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Patients who transfer into the practice may be excluded from the measure. Additional
exclusion criteria are: (1) drugs not typically used in outpatient settings, such as cough and cold
formulations including elixirs, and combination products containing antitussives, decongestants,
antihistamines, and expectorants; (2) all other prescribed opioids not included on this list of commonly
prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html; (3) buprenorphine
products indicated for medication-assisted treatment (MAT) to treat opioid use disorder, identified by
ICD-10 codes.

Data sources

Prescription data from the practice EHR.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm. List of extended-release/long-acting opioids can be found
here: https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251735.htm.
• If there are challenges in the EHR to secure these data, a practice may wish to measure the percentage
of prescriptions that are for immediate-release opioids, instead of at patient level.
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MEASURE 2: CHECK PRESCRIPTION DRUG MONITORING PROGRAM (PDMP) BEFORE PRESCRIBING OPIOIDS
CDC Prescribing Guideline
Recommendation 9

Clinicians should review the patient’s history of controlled substance prescriptions using state PDMP
data to determine whether the patient is receiving opioid dosages or dangerous combinations that put
him or her at high risk for overdose. They should also assess whether the use of multiple prescribers and/or
pharmacies suggests uncoordinated or insufficiently coordinated care. Clinicians should review PDMP data
when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain,
ranging from every prescription to every three months.

Description

The percentage of patients with a new opioid prescription for chronic pain with documentation that
a PDMP was checked prior to prescribing.

Numerator

The number of patients with a new opioid prescription for chronic pain with documentation that a PDMP
was checked prior to prescribing.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older prescribed an opioid for
chronic pain (see Appendix D for ICD-10 codes) who had no opioid prescription in the previous 45 days.

Measurement period

One week (day of or within the week prior to prescribing).

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Additional exclusion criteria are: (1) drugs not typically used in outpatient settings, such
as cough and cold formulations including elixirs, and combination products containing antitussives,
decongestants, antihistamines, and expectorants; (2) all other prescribed opioids not included on this list
of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html; (3)
buprenorphine products indicated for medication-assisted treatment (MAT) to treat opioid use disorder,
identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Access to state PDMP data. A structured field in the EHR
to capture that the PDMP was checked.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Not all clinicians may be registered with the PDMP and practices’ access to the PDMP embedded within
an EHR may not always work. While EHRs can sometimes have a hyperlink to the PDMP or a “single signon” access from the EHR, an indication that the PDMP was checked for a specific patient is not captured.
Practices may need to create a structured field or checkbox for clinicians to indicate the PDMP was
checked. Clinicians should remember to look for benzodiazepine prescriptions from other clinicians, as
well as opioids.
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MEASURE 3: URINE DRUG TESTING BEFORE PRESCRIBING OPIOIDS
CDC Prescribing Guideline
Recommendation 10

When prescribing opioids for chronic pain, clinicians should administer urine drug tests before starting
opioid therapy and at least annually to assess presence of prescribed opioids as well as other controlled
prescription drugs and illicit drugs.

Description

The percentage of patients with a new opioid prescription for chronic pain with documentation
that a urine drug test was performed prior to prescribing.

Numerator

The number of patients with a new opioid prescription for chronic pain with documentation of
a urine drug test.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older prescribed an opioid for
chronic pain (see Appendix D for ICD-10 codes) who had no opioid prescription in the previous 45 days.

Measurement period

One week (day of or within the week prior to prescribing).

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Additional exclusion criteria are: (1) drugs not typically used in outpatient settings, such
as cough and cold formulations including elixirs, and combination products containing antitussives,
decongestants, antihistamines, and expectorants; (2) all other prescribed opioids not included on this list
of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html, all
other prescribed opioids are not included; (3) buprenorphine products indicated for medication-assisted
treatment (MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Urine drug testing data in EHR and/or medical chart.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm. List of extended-release/long-acting opioids can be found here:
https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251735.htm.
• Some systems may not have access to laboratory services in house or the results in a structured field. It is
not only important to determine whether a patient is taking other controlled or illicit substances; it is also
important to determine whether the patient is taking the medication to help prevent opioid diversion.
Practices should check with the labs they use, since mass spectrometry is usually required to test for the
absence of a prescribed medication. A separate order may be required for this confirmation.
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MEASURE 4: EVALUATE WITHIN FOUR WEEKS OF STARTING OPIOIDS
CDC Prescribing Guideline
Recommendation 7

Clinicians should evaluate benefits and harms to patients within one to four weeks of starting opioid
therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued
therapy to patients every three months or more frequently. If benefits do not outweigh harms of continued
opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower
dosages, or to taper and discontinue opioids.

Description

The percentage of patients with a follow-up visit within four weeks of starting an
opioid for chronic pain.

Numerator

The number of patients with a new opioid prescription for chronic pain with an
in-person follow-up visit with the prescribing clinician within four weeks.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older prescribed an opioid for
chronic pain (see Appendix C for ICD-10 codes) who had no opioid prescription in the previous 45 days.

Measurement period

Four weeks (within four weeks of starting opioids).

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Additional exclusions criteria are: (1) drugs not typically used in outpatient settings,
such as cough and cold formulations including elixirs, and combination products containing antitussives,
decongestants, antihistamines, and expectorants; (2) all other prescribed opioids not included on this list of
commonly prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html; (3)
buprenorphine products indicated for medication-assisted treatment (MAT) to treat opioid use disorder,
identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Patient follow-up visit data from the EHR or the medical chart.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• In-person follow-ups should be conducted by the prescribing clinician. However, if it is not feasible to
require that patients would have their follow-up with the prescribing clinician because of staffing, they
may consider revising the measure accordingly (to indicate any clinician).
• Telemedicine or virtual visits are considered “in-person” visits when they are already considered a part
of standard care in a practice.
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MEASURE 5: THREE DAYS' SUPPLY FOR ACUTE PAIN
CDC Prescribing Guideline
Recommendation 6

Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain,
clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no
greater quantity than needed for the expected duration of pain severe enough to require opioids. Three
days or less will often be sufficient; more than seven days will rarely be needed.

Description

The percentage of patients with a new opioid prescription for acute pain
for three days’ supply or less.

Numerator

The number of patients with a new opioid prescription for acute pain
for three days’ supply or less.

Denominator

The number of patients prescribed an opioid for acute pain who had no opioid prescription
in the previous 45 days.
The following is a list of potential acute pain codes, though not exhaustive:
F45.4 Pain disorders related to psychological factors
G44. Headache syndromes
G50.1 Atypical face pain
G43-G44 Migraine and other headache syndromes
G54.6 Phantom limb syndrome with pain
G89.0 Central pain syndrome
G89.1 Acute pain, not elsewhere classified
H92.0 Ear pain
H57.1 Eye pain
K08.8 Tooth pain
M25.5 Joint pain
M25.51 Shoulder pain
M54. Spine pain
M54.9 Back pain
M79.1 Myalgia
M79.6 Limb pain
N64.4 Breast pain
R07.0 Throat pain
R07.1 Chest pain on breathing
R07.9 Chest pain unspecified
R10. Abdomen pain
R10.2 Pelvic and perineal pain
R30.9 Painful urination
R51 Headache
R52 Generalized pain NOS

Measurement period

Practice may determine the period of time.
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Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using
a procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically
used in outpatient settings, such as cough and cold formulations including elixirs, and combination
products containing antitussives, decongestants, antihistamines, and expectorants; (2) all other
prescribed opioids not included on this list of commonly prescribed opioids: https://www.cdc.gov/
drugoverdose/prescribing/guideline.html; (3) buprenorphine products indicated for medicationassisted treatment (MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with
EHR records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm. List of extended-release/long-acting opioids can be found
here: https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251735.htm.
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Long-term Opioid Therapy Measures
MEASURE 6: DOSAGE OF > 50 MMEs
CDC Prescribing Guideline
Recommendation 5

When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use
caution when prescribing opioids at any dosage, carefully reassess evidence of individual benefits and risks
when considering increasing dosage to 50 morphine milligram equivalents (MME) or more per day, and
avoid increasing dosage to 90 MME or more per day or carefully justify a decision to titrate dosage to 90
MME or more per day.

Description

The percentage of patients on long-term opioid therapy who are taking 50 MMEs or more per day.

Numerator

The number of patients taking ≥ 50 MMEs per day.

Denominator

The number of patients in an outpatient panel of patients 18 years of age
or older with ≥ 60 days’ supply of opioids within a quarter.

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Additional exclusions criteria are: (1) drugs not typically used in outpatient settings,
such as cough and cold formulations including elixirs, and combination products containing antitussives,
decongestants, antihistamines, and expectorants; (2) all other prescribed opioids not included on this list of
commonly prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html; (3)
buprenorphine products indicated for medication-assisted treatment (MAT) to treat opioid use disorder,
identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the Sig and add up the
MMEs of all opioid prescriptions.
• Practice could obtain baseline data and then monitor the trend to identify patterns of patients being
potentially escalated from lower doses crossing into the ≥ 50 MMEs per day group.
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MEASURE 7: DOSAGE OF > 90 MMEs
CDC Prescribing Guideline
Recommendation 5

When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use
caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits
and risks when considering increasing dosage to 50 morphine milligram equivalents (MME) or more per
day, and should avoid increasing dosage to 90 MME or more per day or carefully justify a decision to titrate
dosage to 90 MME or more per day.

Description

The percentage of patients on long-term opioid therapy who are taking 90 MMEs or more per day.

Numerator

The number of patients taking ≥ 90 MMEs per day.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply
of opioids within a quarter.

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior;
and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known
[Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code
of terminal condition with (Z51.5), and end-of-life care patients would be identified using a procedure or
CPT code. Note: identifying end-of-life care patients may be difficult to systematically capture; palliative
care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded
from the measure. Additional exclusions criteria are: (1) drugs not typically used in outpatient settings,
such as cough and cold formulations including elixirs, and combination products containing antitussives,
decongestants, antihistamines, and expectorants; (2) all other prescribed opioids not included on this list
of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/prescribing/guideline.html; (3)
buprenorphine products indicated for medication-assisted treatment (MAT) to treat opioid use disorder,
identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR.

Guidance for producing
the measure and
potential challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the Sig and add up the
MMEs of all opioid prescriptions.
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MEASURE 8: CONCURRENT PRESCRIBING OF OPIOIDS AND BENZODIAZEPINES
CDC Prescribing Guideline
Recommendation 11

Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently
whenever possible.

Description

The percentage of patients on long-term opioid therapy who received a prescription for a benzodiazepine.

Numerator

The number of patients prescribed an opioid and a benzodiazepine.

Denominator

The number of patients in an outpatient panel of patients 18 years of age
or older with ≥ 60 days’ supply of opioids within a quarter.

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically used
in outpatient settings, such as cough and cold formulations including elixirs, and combination products
containing antitussives, decongestants, antihistamines, and expectorants; (2) all other prescribed opioids
not included on this list of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/
prescribing/guideline.html; (3) buprenorphine products indicated for medication-assisted treatment
(MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data Sources

Prescription data from the practice EHR.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the MMEs
of all opioid prescriptions.
• Identifying benzodiazepines prescribed to patients in opioid therapy by prescribers in other practices or
healthcare systems will be difficult without accessing the state’s PDMP. PDMP data are not universally
integrated into EHRs, so that may require an additional step.
• If there are challenges in securing these data, a practice may wish to assess whether patients receiving
long-term opioid therapy are also being prescribed benzodiazepines long-term. This can be done by
assessing whether the person received at least 45 days’ supply of benzodiazepines in the quarter, using
the same methods employed for opioids.
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MEASURE 9: FOLLOW-UP VISIT QUARTERLY
CDC Prescribing Guideline
Recommendation 7

Clinicians should evaluate benefits and harms with patients within one to four weeks of starting opioid
therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of
continued therapy with patients every three months or more frequently. If benefits do not outweigh
harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to
taper opioids to lower dosages, or to taper and discontinue opioids.

Description

The percentage of patients on long-term opioid therapy who have a follow-up visit at least quarterly.

Numerator

The number of patients who had at least one in-person follow-up visit with the prescribing clinician
at least quarterly.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply
of opioids within a quarter.

Measurement period

Ninety (90) days.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end of life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically
used in outpatient settings, such as cough and cold formulations including elixirs, and combination
products containing antitussives, decongestants, antihistamines, and expectorants; (2) all other
prescribed opioids not included on this list of commonly prescribed opioids: https://www.cdc.gov/
drugoverdose/prescribing/guideline.html; (3) buprenorphine products indicated for medicationassisted treatment (MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Patient follow-up visit data from the EHR
or the medical chart.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EEHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the MMEs
of all opioid prescriptions.
• It will be challenging to determine whether a visit was related to following-up on long-term opioid
therapy without a chart. A practice should consider the best way to capture visits related to opioids
(e.g., create a structured field, create a registry to track last visits).
• If it is unreasonable to require that patients would have their follow-up with the prescribing clinician
because of staffing, they may consider revising the measure accordingly (to indicate any clinician).
• If there are challenges in securing these data, a practice may wish to look at a six-month interval, and
limit the analyses to persons who were receiving long-term opioid therapy consistently over that time
period. Then one could count the number of visits to the prescribing physician. The simplest metric
would be the percent of long-term opioid therapy patients who have at least one follow-up visit to the
clinician in a six-month period.
o Another option would be to report the percentage of long-term opioid therapy patients with at
least two follow-up visits. However, it would then probably be necessary to extend the time
period from six months to nine months to provide leeway for follow-up visits that fell slightly
outside the month time window.
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MEASURE 10: QUARTERLY PAIN AND FUNCTIONAL ASSESSMENTS
CDC Prescribing Guideline
Recommendation 2

Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients,
including realistic goals for pain and function, and consider how opioid therapy will be discontinued
if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically
meaningful improvement in pain and function that outweighs risks to patient safety.

Description

The percentage of patients on long-term opioid therapy who had at least quarterly pain and
functional assessments.

Numerator

The number of patients with documented pain and functional assessments using a validated clinical
assessment tool (e.g., PEG) at least quarterly.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply of
opioids within a quarter.

Numerator

The number of patients with documented pain and functional assessments using a validated clinical
assessment tool (e.g., PEG) at least quarterly.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice
may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically used in
outpatient settings, such as cough and cold formulations including elixirs, and combination products
containing antitussives, decongestants, antihistamines, and expectorants; (2) all other prescribed opioids
not included on this list of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/
prescribing/guideline.html; (3) buprenorphine products indicated for medication-assisted treatment
(MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. PEG assessment scale data captured outside and recorded
in the EHR or a structured version of the PEG available in the EHR.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with
EHR records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the
MMEs of all opioid prescriptions.
• Would need to create a structured field to capture when assessments were done and, optimally,
the ratings on the PEG each time.
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MEASURE 11: CHECK PDMP QUARTERLY
CDC Prescribing Guideline
Recommendation 9

Clinicians should review the patient’s history of controlled substance prescriptions using state prescription
drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or
dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data
when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain,
ranging from every prescription to every three months.

Description

The percentage of patients on long-term opioid therapy who had documentation that a PDMP
was checked at least quarterly.

Numerator

The number of patients who had documentation that a PDMP was checked at least quarterly.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply
of opioids within a quarter.

Measurement period

Ninety (90) days.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the practice
may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically used in
outpatient settings, such as cough and cold formulations including elixirs, and combination products
containing antitussives, decongestants, antihistamines, and expectorants; (2) all other prescribed opioids
not included on this list of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/
prescribing/guideline.html; (3) buprenorphine products indicated for medication-assisted treatment
(MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Access to state PDMP data. A structured field in the EHR to
capture that the PDMP was checked.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the
MMEs of all opioid prescriptions.
• Not all clinicians may be registered with the PDMP and practices’ access to the PDMP embedded within
an EHR may not always work. While EHRs can sometimes have a hyperlink to the PDMP or a “single signon” access from the EHR, an indication that the PDMP was checked for a specific patient is not captured.
Practices may need to create a structured field or checkbox for clinicians to indicate the PDMP was
checked. Clinicians should remember to look for benzodiazepine prescriptions from other clinicians,
as well as opioids.
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MEASURE 12: COUNSEL ON RISKS AND BENEFITS ANNUALLY
CDC Prescribing Guideline
Recommendation 3

Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks
and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.

Description

The percentage of patients on long-term opioid therapy for whom the clinician counseled the patient
on the risks and benefits of opioids at least annually.

Numerator

The number of patients the clinician counseled on the risks and benefits of opioids at least annually.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply
of opioids within a quarter.

Measurement period

One year.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically
used in outpatient settings, such as cough and cold formulations including elixirs, and combination
products containing antitussives, decongestants, antihistamines, and expectorants; (2) all other
prescribed opioids not included on this list of commonly prescribed opioids: https://www.cdc.gov/
drugoverdose/prescribing/guideline.html; (3) buprenorphine products indicated for medicationassisted treatment (MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Structured field indicating that counseling was provided or
a signed treatment agreement housed in the EHR or the medical chart.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the MMEs
of all opioid prescriptions.
• Data that indicate that counseling was provided would potentially be captured in a clinical note, from
which data is challenging to pull for measurement purposes. A practice may want to create a structured
field or note template to allow this information to be readily queried from an EHR.
• If a practice uses treatment agreements that address risks and benefits and instructs clinicians to
counsel, a practice may wish to use a treatment agreement as an indicator that the patient was
counseled on risks and benefits.
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MEASURE 13: ANNUAL URINE DRUG TEST
CDC Prescribing Guideline
Recommendation 10

When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid
therapy and consider urine drug testing at least annually to assess for prescribed medications as well as
other controlled prescription drugs and illicit drugs.

Description

The percentage of patients on long-term opioid therapy with documentation that a urine drug test was
performed at least annually.

Numerator

The number of patients with documentation of a urine drug test.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply of
opioids within a quarter.

Measurement period

One year.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D]), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically used
in outpatient settings, such as cough and cold formulations including elixirs, and combination products
containing antitussives, decongestants, antihistamines, and expectorants; (2) all other prescribed opioids
not included on this list of commonly prescribed opioids: https://www.cdc.gov/drugoverdose/
prescribing/guideline.html; (3) buprenorphine products indicated for medication-assisted treatment
(MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Urine drug testing data in EHR and/or medical chart.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the MMEs
of all opioid prescriptions.
• Some systems may not have access to laboratory services in house or the results in a structured field. It is
not only important to determine whether a patient is taking other controlled or illicit substances; it is
also important to determine whether the patient is taking the medication to help prevent opioid
diversion. Practices should check with the labs they use, since mass spectrometry is usually required to
test for the absence of a prescribed medication. A separate order may be required for this confirmation.
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MEASURE 14: REFERRAL FOR NONPHARMACOLOGICAL THERAPY
CDC Prescribing Guideline
Recommendation 1

Nonpharmacological therapy and non-opioid pharmacologic therapy are preferred for chronic
pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function
are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with
nonpharmacological therapy and non-opioid pharmacologic therapy, as appropriate.

Description

The percentage of patients with chronic pain who had at least one referral or visit to nonpharmacologic
therapy as a treatment for pain.

Numerator

The number of patients who had at least one referral to nonpharmacologic therapy (e.g., physical therapy,
exercise therapy, cognitive behavioral therapy, weight loss).
Current Procedural Terminology (CPT) codes cover procedures. Therapies are procedures, so the Z51.89
ICD-10 code is under a broad code for “Encounter for other specified aftercare.” All outpatient clinicians
use CPT codes to bill insurance along with ICD diagnoses codes. CPT codes were added for the therapies
below when appropriate codes could be determined. The Healthcare Common Procedure Coding System
(HCPCS) is a set of health care procedure codes based on the American Medical Association's (AMA)
Current Procedural Terminology. Level I codes consist of the AMA CPT code and are numeric. Level II codes
are alphanumeric and primarily include non-physician services such as ambulance services and prosthetic
devices, and represent items and supplies and non-physician services, not covered by CPT-4 codes (Level I).
Some of these non-physician services may use HCPCS codes. Some of these codes include;
• physical therapy (ICD-10: Z51.89); CPT: 97001-97039, but could also include areas noted in
interventional procedure codes below),
• exercise therapy (ICD-10: Z51.89) (CPT: 97110 = therapeutic exercises, but could add aquatic therapy,
etc.),
• cognitive behavioral therapy,
• weight loss HCPCS/CPT Codes G0447— face-to-face behavioral counseling for obesity, 15 minutes
G0473—face-to-face behavioral counseling for obesity, group (2–10), 30 minutes. The related
diagnoses are: ICD-10 Codes Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35, Z68.36, Z68.37, Z68.38,
Z68.39, Z68.41, Z68.42, Z68.43, Z68.44, or Z68.45, and
• non-invasive therapies could include CPT: Therapeutic Procedures 97110 -97546, or more broadly
to include Medical Nutritional Therapy, Wound Care, Acupuncture, Osteopathic Manipulations and
Chiropractic care, through 98943, and more.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with chronic pain (see
Appendix C for ICD-10 codes).

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms; ICD
10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain behavior; and
ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not known [Appendix
D]), palliative care and end-of-life care. Palliative care is identified with a principal ICD-10 code of terminal
condition with (Z51.5), and end-of-life care patients would be identified using a procedure or CPT code.
Note: identifying end-of-life care patients may be difficult to systematically capture; palliative care may
be a sufficient proxy for end-of-life care. Patients who transfer into the practice may be excluded from the
measure.

Data sources

Prescription data from the practice EHR. Diagnosis code data from the practice EHR and procedural
code data for the non-pharmacological therapy.
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• Capturing referrals: There can be challenges measuring referrals in EHRs. Some EHRs may capture in a
structured field whether a patient has been referred within the same health care system. However, if a
patient is referred to a professional outside of the system, it may not be captured as a structured field.
Some types of referrals may not be captured via anything other than a recommendation in the clinical
note.
• A practice should consider focusing on a specific chronic condition to make it easier to operationalize
this measure, such as the percentage of patients with chronic low back pain who had at least one
referral to physical therapy. Alternatively, focus on osteoarthritis, given how common it is.
• Another challenge may be that patients who have had a chronic condition for several years may have
been referred to nonpharmacological therapy years ago, which would be difficult to capture.
• If there are challenges in securing these data, a practice may wish to focus on patients on long-term
opioid therapy (as the denominator), although the measure could worsen over time if patients are being
put on nonpharmacologic therapy instead of opioids.
o Or, a practice could calculate the percentage of patients with chronic low back pain who had at least
one referral to physical therapy.
• If a practice wants to define appropriate nonpharmacologic pain treatments for a particular condition
and develop an operational definition of the initiation of an episode of care, they could track the
percent of patients who received an appropriate nonpharmacologic treatment.
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MEASURE 15: NALOXONE COUNSELING AND PRESCRIBED OR REFERRED
CDC Prescribing Guideline
Recommendation 8

Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk
factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to
mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose,
such as history of overdose, history of substance use disorder, higher opioid dosages (≥50MME/d), or
concurrent benzodiazepine use, are present.

Description

The percentage of patients on long-term opioid therapy who were counseled on the purpose and use of
naloxone, and either prescribed or referred to obtain naloxone.

Numerator

The number of patients counseled on the purpose and use of naloxone, and either prescribed or referred
to obtain naloxone.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with ≥ 60 days’ supply
of opioids within a quarter AND on ≥ 50 MMEs per day, OR diagnosis of opioid use disorder (OUD), OR
diagnosis of substance abuse, OR taking benzodiazepines concurrently, OR a diagnosis of restrictive or
obstructive lung disease, and/or sleep apnea.

Measurement period

Practice may determine the period of time.

Exclusions

Exclusion criteria include cancer patients (ICD-10 codes C00-D09 are “cancers,” malignant neoplasms;
ICD-10 codes D10-D3A are benign neoplasms; ICD-10 codes D37-D48 are neoplasms of uncertain
behavior; and ICD-10 code D49 is a neoplasm of unspecified behavior—could be malignant, but not
known [Appendix D), palliative care and end-of-life care. Palliative care is identified with a principal
ICD-10 code of terminal condition with (Z51.5), and end-of-life care patients would be identified using a
procedure or CPT code. Note: identifying end-of-life care patients may be difficult to systematically
capture; palliative care may be a sufficient proxy for end-of-life care. Patients who transfer into the
practice may be excluded from the measure. Additional exclusions criteria are: (1) drugs not typically
used in outpatient settings, such as cough and cold formulations including elixirs, and combination
products containing antitussives, decongestants, antihistamines, and expectorants; (2) all other
prescribed opioids not included on this list of commonly prescribed opioids: https://www.cdc.gov/
drugoverdose/prescribing/guideline.html; (3) buprenorphine products indicated for medicationassisted treatment (MAT) to treat opioid use disorder, identified by ICD-10 codes.

Data sources

Prescription data from the practice EHR. Naloxone counseling and referral data from the EHR
or medical chart review.

Guidance for producing
the measure and potential
challenges

• Identifying opioid medications: EHRs may not be able to identify all opioid medications reliably. The
associated National Drug Code (NDC), generic name, and product name, can be used to match with EHR
records. See the FDA’s National Drug Code Directory: https://www.fda.gov/Drugs/
InformationOnDrugs/ucm142438.htm.
• Unknown days’ supply in EHRs: Practices lacking information about days’ supply could calculate the
days’ supply by dividing the prescription quantity by the maximum use per the sig and add up the
MMEs of all opioid prescriptions.
• Capturing referrals: There can be challenges measuring referrals in EHRs. Some EHRs may capture in a
structured field whether a patient has been referred within the same health care system. If a patient is
referred to a professional outside of the system, it may not be captured as a structured field. Some types
of referrals may not be captured via anything other than a recommendation in the clinical note.
• Counseling is not captured as a structured field in EHRs. Practices may have to create a field or checkbox to indicate counseling was provided.

Alternatives for
the Measure

If a practice is unable to identify patients in ALL risk categories, an alternative is to identify those in risk
categories that are feasible (e.g., ≥ 50 MMEs or concurrent use of benzodiazepines). Practices may want to
examine the percentage who received a naloxone prescription, separately from whether counseling was
provided. The former may be more readily available in most practices’ existing data, and separating these
two may facilitate better clarity on what to target for improvement.
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MEASURE 16: MEDICATION-ASSISTED TREATMENT (MAT)
CDC Prescribing Guideline
Recommendation 12

Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with
naltrexone, buprenorphine, or methadone in combination with behavioral therapies) for patients with
opioid use disorder.

Description

The percentage of patients with an opioid use disorder who were referred to or prescribed medication
assisted treatment.

Numerator

The number of patients who were referred to a methadone treatment program, or were prescribed/
referred for treatment with naltrexone, buprenorphine, or buprenorphine/naloxone.

Denominator

The number of patients in an outpatient panel of patients 18 years of age or older with a diagnosis of
opioid use disorder (OUD).

Measurement period

Practice may determine the period of time.

Exclusions

Some formulations of buprenorphine (e.g, belbuca, butrans) are prescribed for pain, these would need
to be excluded.

Data sources

Guidance for producing
the measure and potential
challenges

Prescription data from the practice EHR. Diagnosis data for OUD in EHR. Referral data in EHR or
medical chart for medication-assisted treatment (MAT), or prescription data for naltrexone or
buprenorphine/naloxone.
• EHRs may not be able to identify all opioid medications reliably. The associated National Drug Code
(NDC), generic name, and product name, can be used to match with EHR records. See the FDA’s National
Drug Code Directory: https://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm.
• Capturing referrals: There can be challenges measuring referrals in EHRs. Some EHRs may capture in a
structured field whether a patient has been referred within the same health care system. If a patient is
referred to a professional outside of the system, it will not be captured as a structured field. Some types
of referrals may not be captured via anything other than a recommendation in the clinical note.
• Practices may need to create a field in the EHR to capture referrals for MAT, since methadone clinics
are often separate entities.

Alternatives for
the measure

• Practices could focus on measuring specific MAT, based on what your patient panel has access to
or where your practice is aiming to improve access.
• The simplest measure would be the percentage of the adult population (or the number per 1,000
population) using buprenorphine. Tracking this over time would be useful for tracking whether these
drugs were being prescribed more frequently.
• In order to link prescribing of buprenorphine to patients who have received opioids for chronic pain, one
option might be to measure the percentage of persons who received long-term opioid therapy
at any time in a year who also received buprenorphine in the same year. This would provide a rough
indication of the rate of transition from prescription opioids to MAT.
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Self-assessment Questionnaire for Health Systems
This self-assessment questionnaire is for health systems pursuing an opioid quality improvement (QI) initiative
to improve their opioid prescribing practices. The questionnaire serves two purposes—as a tool for reflecting
on progress implementing the “five-steps” (Exhibit 2) at baseline and periodically throughout the QI initiative.
Secondly, it includes questions to ascertain the extent to which care provided is consistent with the CDC
Prescribing Guideline. The questionnaire is based on the prior work of several individuals.4

▶ Part I is for the QI effort lead(s) to reflect on and indicate their system’s status in progressing

through the five steps to implementing the CDC Guideline for Prescribing Opioids for Chronic Pain
recommendations and using the quality improvement (QI) measures.

▶ Part II of the self-assessment questionnaire asks systems to indicate the extent to which

clinicians in their system provide care consistent with each of the CDC Prescribing Guideline
recommendations. Ideally, the clinical QI opioid measures (Exhibit 1) would be used to measure
the extent to which care is concordant with CDC Prescribing Guideline, but in the
absence of the measures this questionnaire may serve as a helpful assessment.

This survey can be completed by a single individual leading the QI effort or by several people involved
in the initiative and serve as a point of feedback if people have different assessments on the status of
implementation, or the extent to which clinicians are providing care consistent with the CDC Prescribing
Guideline recommendations.
When the survey is completed by multiple individuals, you can calculate an average on each of the steps in
Part I. For Part II you can sum the responses by category, or even combine the top two categories if "very
often" or "always" are sufficient targets for your system on the CDC Prescribing Guideline recommendations.

4 The self-assessment questionnaire is loosely based on the 6 Building Blocks self-assessment questionnaire,
and its various iterations, developed by Michael Parchman, Mark Stephens and Laura Heesacker.
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PART I: Status of Implementation Steps
On a scale from 1 to 5, with 1 being you have not begun to 5 being you are done (for now), please
indicate your health system’s current status with the tasks/activities within each of the five steps.
Circle the response that best represents where your system is at for every task/activity with each step.
1

2

3

4

5

Have not begun

Have begun

In progress

Mostly done

Done (for now)

Step 1: Obtain leadership support and identify a champion(s)
1. Obtain leadership support

1

2

3

4

5

2. Identify a champion(s) to drive the change process

1

2

3

4

5

3. Identify and engage a change team, or key staff

1

2

3

4

5

4. Allocate resources to support champion
and/or change team

1

2

3

4

5

5. Consider the readiness of your system and
potential barriers to implementing changes

1

2

3

4

5

Step 2: Assess current approach to opioids and identify areas for improvement
6. Assess current policies and practices

1

2

3

4

5

7. Have key staff complete this self-assessment
questionnaire

1

2

3

4

5

8. Collect data on your patient population
on opioid therapy

1

2

3

4

5

9. Determine access to specialists and
other needed resources

1

2

3

4

5

10. Identify areas of practice in need of improvement

1

2

3

4

5

Step 3: Progress towards implementation of guideline recommendations
11. Consider practice-level changes

1

2

3

4

5

12. Decide which Guideline recommendations
to implement

1

2

3

4

5

13. Prioritize what will be implemented

1

2

3

4

5

1

2

3

4

5

Step 4: Define system goals
14. Set measurable goals

Step 5: Develop a plan, implement and monitor progress
15. Develop a plan for implementing selected
Guideline recommendations

1

2

3

4

5

16. Implement selected Guideline recommendations

1

2

3

4

5

17. Monitor progress using the QI measures
and other data

1

2

3

4

5
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PART II: Extent to Which Care Provided is Consistent
with the CDC Prescribing Guideline Recommendations
How often do clinicians in your system provide care consistent with the following the CDC
Prescribing Guideline recommendation statements? Mark your response with an “X” in the box.
Nonpharmacologic and nonopioid therapies
(recommendation 1)

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Nonpharmacologic therapy and nonopioid
pharmacologic therapy are preferred for chronic
pain. Clinicians should consider opioid therapy only
if expected benefits for both pain and function are
anticipated to outweigh risks to the patient.
If opioids are used, they should be combined
with nonpharmacologic therapy and nonopioid
pharmacologic therapy, as appropriate.

Pain and functional assessment
(recommendation 2)
Before starting opioid therapy for chronic pain,
clinicians should establish treatment goals with
all patients, including realistic goals for pain and
function, and consider how opioid therapy will be
discontinued if benefits do not outweigh risks.
Clinicians should continue opioid therapy only if
there is clinically meaningful improvement in pain
and function that outweighs risks to patient safety.

Counsel on risks and benefits
(recommendation 3)
Before starting and periodically during opioid
therapy, clinicians should discuss with patients
known risks and realistic benefits of opioid therapy
and patient and clinician responsibilities for
managing therapy.

Prescribe immediate release opioids
(recommendation 4)
When starting opioid therapy for chronic pain,
clinicians should prescribe immediate-release
opioids instead of extended-release/long-acting
(ER/LA) opioids.
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Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

When opioids are started, clinicians should
prescribe the lowest effective dosage. Clinicians
should use caution when prescribing opioids at
any dosage, should carefully reassess evidence
of individual benefits and risks when considering
increasing dosage to 50 morphine milligram
equivalents (MME) or more per day.
Clinicians should avoid increasing dosage to 90
MME or more per day or carefully justify a decision
to titrate dosage to 90 MME or more per day.

Limit days’ supply for acute pain
(recommendation 6)
Long-term opioid use often begins with treatment
of acute pain. When opioids are used for acute pain,
clinicians should prescribe the lowest effective dose
of immediate-release opioids.
When opioids are used for acute pain, clinicians
should prescribe no greater quantity than needed
for the expected duration of pain severe enough
to require opioids. Three days or less will often
be sufficient; more than seven days will rarely be
needed.

Follow-up within four weeks
(recommendation 7)
Clinicians should evaluate benefits and harms
with patients within 1 to 4 weeks of starting opioid
therapy for chronic pain or of dose escalation.
Clinicians should evaluate benefits and harms of
continued therapy with patients every 3 months
or more frequently.
If benefits do not outweigh harms of continued
opioid therapy, clinicians should optimize other
therapies and work with patients to taper opioids to
lower dosages, or to taper and discontinue opioids.

Naloxone (recommendation 8)
Before starting and periodically during continuation
of opioid therapy, clinicians should evaluate risk
factors for opioid-related harms.
Clinicians should incorporate into the
management plan strategies to mitigate
risk, including considering offering naloxone
when factors that increase risk for opioid overdose,
such as history of overdose, history of substance
use disorder, higher opioid dosages (≥50MME/d),
or concurrent benzodiazepine use, are present.
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Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Never

Rarely

Sometimes

Very often

Always

Clinicians should review the patient’s history of
controlled substance prescriptions using state
prescription drug monitoring program (PDMP)
data to determine whether the patient is receiving
opioid dosages or dangerous combinations that
put him or her at high risk for overdose. Clinicians
should review PDMP data when starting opioid
therapy for chronic pain.
Clinicians should review PDMP data periodically
during opioid therapy for chronic pain, ranging from
every prescription to every 3 months.

Urine drug testing (recommendation 10)
When prescribing opioids for chronic pain, clinicians
should administer urine drug tests before starting
opioid therapy to assess presence of prescribed
opioids as well as other controlled prescription drugs
and illicit drugs.
When prescribing opioids for chronic pain, clinicians
should administer urine drug tests at least annually
to assess presence of prescribed opioids as well as
other controlled prescription drugs and illicit drugs.

Co-prescribing Benzodiazepines
(recommendation 11)
Clinicians should avoid prescribing opioid pain
medication and benzodiazepines concurrently
whenever possible.

Buprenorphine (recommendation 12)
Clinicians should offer or arrange evidence-based
treatment (usually medication-assisted treatment
with buprenorphine or methadone in combination
with behavioral therapies) for patients with opioid
use disorder.
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Neoplasms

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

C00-C14 Malignant neoplasms of lip, oral cavity, and pharynx
C15-C26 Malignant neoplasms of digestive organs
C30-C39 Malignant neoplasms of respiratory and intrathoracic organs
C40-C41 Malignant neoplasms of bone and articular cartilage
C43-C44 Melanoma and other malignant neoplasms of skin
C45-C49 Malignant neoplasms of mesothelial and soft tissue
C50-C50 Malignant neoplasms of breast
C51-C58 Malignant neoplasms of female genital organs
C60-C63 Malignant neoplasms of male genital organs
C64-C68 Malignant neoplasms of urinary tract
C69-C72 Malignant neoplasms of eye, brain, and other parts of central
nervous system
C73-C75 Malignant neoplasms of thyroid and other endocrine glands
C7A-C7A Malignant neuroendocrine tumors
C7B-C7B Secondary neuroendocrine tumors
C76-C80 Malignant neoplasms of ill-defined, other secondary
and unspecified sites
C81-C96 Malignant neoplasms of lymphoid, hematopoietic,
and related tissue
D00-D09 In situ neoplasms
D10-D36 Benign neoplasms, except benign neuroendocrine tumors
D3A-D3A Benign neuroendocrine tumors
D37-D48 Neoplasms of uncertain behavior, polycythemia vera,
and myelodysplastic syndromes
D49-D49 Neoplasms of unspecified behavior
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

274

Gout

M1A.xxx

Chronic Gout

274

Gout

M10.xxx

Gout

307.8

Pain disorders related to
psychological factors

F45.4x

Pain disorders related to
psychological factors

307.8

Pain disorders related to
psychological factors

G44.209

Tension-type headache,
unspecified, not intractable

337.20337.29

Reflex sympathetic dystrophy

G90.5xxx

Complex regional pain syndrome I

338.0

Central pain syndrome

G89.0

Central pain syndrome

338.2

Chronic Pain

G89.2x

Chronic pain, not elsewhere
classified

338.21

Chronic pain due to trauma

G89.21

Chronic pain due to trauma

338.22

Other chronic postoperative pain

G89.22

Chronic post-thoracotomy pain

338.28

Chronic postop pain, not
elsewhere classified

G89.28

Other chronic postprocedural pain

338.29

Other chronic pain

G89.29

Other chronic pain

338.4

Chronic pain syndrome

G89.4

Chronic pain syndrome

339

Other headache syndromes

G44.xxx

Other headache syndromes

346

Migraine

G43.xxx

Migraine

350

Trigeminal nerve disorders

G50.x

Disorders of trigeminal nerve

350

Trigeminal nerve disorders

B02.22

Postherpetic trigeminal neuralgia

353.0

Brachial plexis lesions

G54.0

Brachial plexus disorders

353.6

Phantom limb syndrome

G54.6

Phantom limb syndrome
with pain

354

Mononeuritis of upper limb
(and mononeuritis multiplex)

G56.xx

Mononeuropathies of
upper limb

354.5

Mononeuritis multiplex

G58.7

Mononeuritis multiplex

355.9

Causalgia

G58.9

Mononeuropathy, unspecified

354.4

Causalgia of upper limb

G56.4x

Causalgia of upper limb
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

355.71

Causalgia of lower limb

G57.7x

Causalgia of lower limb

710

Diffuse diseases of connective
tissues

M32.xx

Systemic lupus erythematosus
(SLE)

710

Diffuse diseases of connective
tissues

M33.xx

Dermatopolymyositis

710

Diffuse diseases of connective
tissues

M34.xx

Systemic sclerosis [scleroderma]

710

Diffuse diseases of connective
tissues

M35.xx

Other systemic involvement of
connective tissue

710

Diffuse diseases of connective
tissues

M36.xx

Systemic disorders of connective
tissue in diseases classified
elsewhere

712

Crystal arthropathies

M11.xxx

Other crystal arthropathies

713

Arthopathy associated with
other disorders

M02.0xx

Arthropathy following intestinal
bypass

713

Arthopathy associated with
other disorders

M02.2xx

Postimmunization arthropathy

713

Arthopathy associated with
other disorders

M02.9

Reactive arthropathy, unspecified

713

Arthopathy associated with
other disorders

M07

Enteropathic arthropathies

713

Arthopathy associated with
other disorders

M14.xxx

Arthropathies in other diseases
classified elsewhere

713

Arthopathy associated with
other disorders

M12.80

Other specific arthropathies, not
elsewhere classified, unspecified
site

713

Arthopathy associated with
other disorders

M36.2

Hemophilic arthropathy

713

Arthopathy associated with
other disorders

M36.3

Arthropathy in other blood
disorders

714

Rheumatoid arthritis and other
inflammatory polyarthropathies

M05.xxx

Rheumatoid arthritis with
rheumatoid factor

714

Rheumatoid arthritis and other
inflammatory polyarthropathies

M06.xxx

Other rheumatoid arthritis

714

Rheumatoid arthritis and other
inflammatory polyarthropathies

M08.xx

Juvenile arthritis

714

Rheumatoid arthritis and other
inflammatory polyarthropathies

M12.0xx

Chronic postrheumatic
arthropathy [Jaccoud]
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

715

Osteoarthrosis and allied
disorders

M15-M19

Osteoarthritis

716

Other and unspecified
arthropathies

M12.1xx

Kaschin-Beck disease

716

Other and unspecified
arthropathies

M12.5xx

Traumatic arthropathy

716

Other and unspecified
arthropathies

M12.8xx

Other specific arthropathies, not
elsewhere classified

716

Other and unspecified
arthropathies

M12.9

Arthropathy, unspecified

717

Internal derangement of knee

M22.4x

Chondromalacia patellae

717

Internal derangement of knee

M23

Internal derangement of knee

717

Internal derangement of knee

S83.0xxx

Subluxation and dislocation
of patella

717

Internal derangement of knee

S83.1xxx

Subluxation and dislocation of
knee

717

Internal derangement of knee

S83.2xxx

Tear of meniscus, current injury

717

Internal derangement of knee

S83.4xxx

Sprain of collateral ligament of
knee

717

Internal derangement of knee

S83.5xxx

Sprain of cruciate ligament of
knee

717

Internal derangement of knee

S83.6xxx

Sprain of the superior tibiofibular
joint and ligament

717

Internal derangement of knee

S83.8xxx

Sprain of other specified parts
of knee

717

Internal derangement of knee

S83.9xxx

Sprain of unspecified site of knee

718.0

Articular cartilage disorder

M24.1xx

Other articular cartilage disorders

718.0

Articular cartilage disorder

S83.3xxx

Tear of articular cartilage of knee,
current

718.1

Loose body in joint

M24.0xx

Loose body in joint

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M45

Ankylosing spondylitis

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M46.0x

Spinal enthesopathy
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M46.1

Sacroiliitis, not elsewhere
classified

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M46.5x

Other infective spondylopathies

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M46.8x

Other specified inflammatory
spondylopathies

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M46.9x

Unspecified inflammatory
spondylopathy

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M48.8Xx

Other specified spondylopathies

720

Ankylosing spondylitis and other
inflammatory spondylopathies

M49.8x

Spondylopathies in diseases
classified elsewhere

721

Spondylosis and allied disorders

M47

Spondylosis

721

Spondylosis and allied disorders

M48.1x

Ankylosing hyperostosis
[Forestier]

721

Spondylosis and allied disorders

M48.2x

Kissing spine

721

Spondylosis and allied disorders

M48.3

Traumatic spondylopathy

721

Spondylosis and allied disorders

M48.9

Spondylopathy, unspecified

722

Intervertebral disc disorders

M46.4x

Discitis, unspecified

722

Intervertebral disc disorders

M50

Cervical disc disorders

722

Intervertebral disc disorders

M51

Thoracic, thoracolumbar, and
lumbosacral intervertebral disc
disorders

722

Intervertebral disc disorders

M96.1

Postlaminectomy syndrome, not
elsewhere classified

722

Intervertebral disc disorders

S13

Dislocation and sprain of joints
and ligaments at neck level

722

Intervertebral disc disorders

S23

Dislocation and sprain of joints
and ligaments of thorax

722

Intervertebral disc disorders

S33

Dislocation and sprain of joints
and ligaments of lumbar spine
and pelvis

723.0

Spinal stenosis in cervical region

M48.02

Spinal stenosis, cervical region

723.1

Cervicalgia

M54.2

Cervicalgia
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

723.2

Cervicocranial syndrome

M53.0

Cervicocranial syndrome

723.3

Cervicobrachial syndrome
(diffuse)

M53.1

Cervicobrachial syndrome

724

Other and unspecified disorders
of back

M48.00M48.01,
M48.03M48.08-

Spinal stenosis

724

Other and unspecified disorders
of back

M43.2x

Fusion of spine

724

Other and unspecified disorders
of back

M43.8X9

Other specified deforming
dorsopathies, site unspecified

724

Other and unspecified disorders
of back

M53.2X7

Spinal instabilities, lumbosacral
region

724

Other and unspecified disorders
of back

M53.2X8

Spinal instabilities, sacral and
sacrococcygeal region

724

Other and unspecified disorders
of back

M53.3

Sacrococcygeal disorders, not
elsewhere classified

724

Other and unspecified disorders
of back

M53.8x

Other specified dorsopathies

724

Other and unspecified disorders
of back

M53.9

Dorsopathy, unspecified

724

Other and unspecified disorders
of back

M54.03

Panniculitis affecting regions of
neck and back, cervicothoracic
region

724

Other and unspecified disorders
of back

M54.04

Panniculitis affecting regions of
neck and back, thoracic region

724

Other and unspecified disorders
of back

M54.05

Panniculitis affecting regions of
neck and back, thoracolumbar
region

724

Other and unspecified disorders
of back

M54.06

Panniculitis affecting regions of
neck and back, lumbar region

724

Other and unspecified disorders
of back

M54.07

Panniculitis affecting regions
of neck and back, lumbosacral
region

724

Other and unspecified disorders
of back

M54.08

Panniculitis affecting regions
of neck and back, sacral and
sacrococcygeal region

724

Other and unspecified disorders
of back

M54.09

Panniculitis affecting regions,
neck and back, multiple sites
in spine
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

724

Other and unspecified disorders
of back

M54.3x

Sciatica

724

Other and unspecified disorders
of back

M54.4x

Lumbago with sciatica

724

Other and unspecified disorders
of back

M54.5

Low back pain

724

Other and unspecified disorders
of back

M54.6

Pain in thoracic spine

724

Other and unspecified disorders
of back

M54.89

Other dorsalgia

724

Other and unspecified disorders
of back

M54.9

Dorsalgia, unspecified

724

Other and unspecified disorders
of back

S12

Fracture of cervical vertebra and
other parts of neck

724

Other and unspecified disorders
of back

S14

Injury of nerves and spinal cord
at neck level

724

Other and unspecified disorders
of back

S22

Fracture of rib(s), sternum,
and thoracic spine

724

Other and unspecified disorders
of back

S24

Injury of nerves and spinal cord
at thorax level

724

Other and unspecified disorders
of back

S32

Fracture of lumbar spine and
pelvis

724

Other and unspecified disorders
of back

S34

Injury of lumbar and sacral spinal
cord and nerves at abdomen,
lower back, and pelvis level

725

Polymyalgia rheumatica

M35.3

Polymyalgia rheumatica

725

Polymyalgia rheumatica

M31.5

Giant cell arteritis with
polymyalgia rheumatica

726

Peripheral enthesopathies and
allied syndromes

M25.7

Osteophyte

726

Peripheral enthesopathies and
allied syndromes

M70.1x

Bursitis of hand

726

Peripheral enthesopathies and
allied syndromes

M70.2x

Olecranon bursitis

726

Peripheral enthesopathies and
allied syndromes

M70.3x

Other bursitis of elbow

726

Peripheral enthesopathies and
allied syndromes

M70.4x

Prepatellar bursitis
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

726

Peripheral enthesopathies and
allied syndromes

M70.5x

Other bursitis of knee

726

Peripheral enthesopathies and
allied syndromes

M70.6x

Trochanteric bursitis

726

Peripheral enthesopathies and
allied syndromes

M70.7x

Other bursitis of hip

726

Peripheral enthesopathies and
allied syndromes

M75

Shoulder lesions

726

Peripheral enthesopathies and
allied syndromes

M76

Enthesopathies, lower limb,
excluding foot

726

Peripheral enthesopathies and
allied syndromes

M77

Other enthesopathies

727.0

Synovitis and tenosynovitis

D48.1

Neoplasm of uncertain behavior
of connective and other soft
tissue

727.0

Synovitis and tenosynovitis

M65

Synovitis and tenosynovitis

727.0

Synovitis and tenosynovitis

M67.3xx

Transient synovitis

727.1

Bunion

M20.1x

Hallux valgus (acquired)

727.1

Bunion

M21.61x

Bunion

727.1

Bunion

M21.62x

Bunionette

727.2

Specific bursitides often of
occupational origin

M70.0xx

Crepitant synovitis (acute)
(chronic) of hand and wrist

727.3

Other bursitis

M71.1xx

Other infective bursitis

727.3

Other bursitis

M71.5xx

Other bursitis, not elsewhere
classified

727.4

Ganglion and cyst of synovium
tendon and bursa

M67.4xx

Ganglion

727.4

Ganglion and cyst of synovium
tendon and bursa

M71.3xx

Other bursal cyst

729.0

Rheumatism, unspecified and
fibrositis

M79.0

Rheumatism, unspecified

729.1

Myalgia and myositis, unspecified

M79.7

Fibromyalgia

729.1

Myalgia and myositis, unspecified

M79.1

Myalgia

729.1

Myalgia and myositis, unspecified

M60.8xx

Other myositis
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ICD-9 DESCRIPTION

ICD-10 CODE

ICD-10 DESCRIPTION

729.1

Myalgia and myositis, unspecified

M60.9

Myositis, unspecified

729.2

Neuralgia, neuritis, and radiculitis,
unspecified

M54.1x

Radiculopathy

729.2

Neuralgia, neuritis, and radiculitis,
unspecified

M54.81

Occipital neuralgia

729.2

Neuralgia, neuritis, and radiculitis,
unspecified

M79.2

Neuralgia and neuritis,
unspecified

729.5

Pain in limb

M79.6xx

Pain in limb, hand, foot, fingers,
and toes

729.7

Nontraumatic compartment
syndrome

M79.Axx

Nontraumatic compartment
syndrome

780.96

Generalized pain

R52

Pain, unspecified

784.0

Headache

R51

Headache

784.0

Headache

G44.1

Vascular headache, not elsewhere
classified
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Toolkit Part A.

Examples of Comprehensive Management Approaches
▶ There are several existing resources that outline the components of safer management of long-term
opioid therapy, including:

•

Kaiser Permanente’s Patients on Chronic Opioid Therapy for Chronic Non-Cancer Pain Safety Guideline
(https://www.ghc.org/static/pdf/public/guidelines/opioid.pdf); and

•

Oregon Pain Guidance’s Opioid Prescribing Guidelines (http://www.oregonpainguidance.org/wp-content/
uploads/2014/04/OPG_Guidelines.pdf).

▶ There is also literature on different practices’ and organizations’ approaches to managing long-term
opioid therapy:

1. Anderson D, Wang S, Zlateva I. Comprehensive assessment of chronic pain management in primary care:
A first phase of a quality improvement initiative at multisite Community Health Center. Quality in Primary
Care. 2012;20.
2. Anderson DR, Zlateva I, Coman EN, Khatri K, Tian T, Kerns RD. Improving pain care through implementation
of the Stepped Care Model at a multisite community health center. Journal of pain research. 2016;9:1021.
3. Cahana A, Dansie EJ, Theodore BR, Wilson HD, Turk DC. Redesigning delivery of opioids to optimize pain
management, improve outcomes, and contain costs. Pain Medicine. 2013;14:36-42.
4. Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multi-disciplinary disease management program for
opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC
Health Services Research. 2005;5(3).
5. Dorflinger L, Moore B, Goulet J, et al. A partnered approach to opioid management, guideline concordance
care and the stepped care model of pain management. Journal of General Internal Medicine. 2014.
6. Eaton LH, Gordon DB, Wyant S, et al. Development and implementation of a telehealth-enhanced
intervention for pain and symptom management. Contemporary clinical trials. 2014;38(2):213-220.
7. Losby JL, Hyatt JD, Kanter MH, Baldwin G, and Matsuoka D. Safer and more appropriate opioid prescribing:
a large healthcare system's comprehensive approach. J Eval Clin Pract. 2017 Jul 14.
8. Moore BA, Anderson D, Dorflinger L, et al. Stepped care model of pain management and quality of pain care
in long-term opioid therapy. J Rehabil Res Dev. 2016;53(1):137-46.
9. Morasco, Benjamin J., et al. "Care management practices for chronic pain in veterans prescribed high doses
of opioid medications." Family practice 30.6 (2013): 671-678.
10. Pade PA, Cardon KE, Hoffman RM, Geppert CMA. Prescription opioid abuse, chronic pain, and primary
care: A co-occurring disorders clinic in the chronic disease model. Journal of Substance Abuse Treatment.
2012;43:446-450.
11. Parchman ML, Von Korff M, Baldwin LM, Stephens M, Ike B, Cromp D, Hsu C, Wagner EH. Primary care clinic
re-design for prescription opioid management. The Journal of the American Board of Family Medicine. 2017
Jan 1;30(1):44-51.
12. Von Korff M, Dublin S, Walker RL, Parchman M, Shortreed SM, Hansen RN, Saunders K. The impact of opioid
risk reduction initiatives on high-dose opioid prescribing for patients on chronic opioid therapy. The Journal
of Pain. 2016 Jan 31;17(1):101-10.
13. Westanmo A, Marshall P, Jones E, Burns K, Krebs EE. Opioid Dose Reduction in a VA Health Care System—
Implementation of a Primary Care Population‐Level Initiative. Pain Medicine. 2015.
14. Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed
approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. Oct-Nov
2007;8(7):573-584.
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Toolkit Part B.

Examples of Local Healthcare System Policies
▶ The following are examples of policies for managing and coordinating long-term opioid therapy:
• The practice develops an administrative definition of long-term opioid therapy to enable identification

of long-term opioid therapy patients (e.g. receiving at least 70 days’ supply of opioids in a 90-day period).

•

The practice develops an administrative definition to identify patients potentially transitioning into
long-term opioid use (e.g., filling a third opioid prescription within six months when not identified as
a long-term opioid therapy patient).

•

Long-term opioid therapy patients receiving daily doses in excess of 90 Morphine Milligram Equivalent
(MME) should have their opioid regimen reviewed by a pain and/or rehabilitation medicine specialist.

•
•
•
•

Providers obtain signed, informed consent from patients initiating long-term opioid therapy.

•

Guidance for appropriate duration of opioid prescriptions (e.g., 3-7 days) for managing common
acute pain conditions.

•

The practice will not provide opioid pain medicines to long-term opioid therapy patients already getting
opioids from other healthcare providers.

•

Patients on particularly high-dose opioids (e.g., 200 MME) have their use reviewed by a pain medicine
specialist every month.

•

The practice checks the prescription drug monitoring program (PDMP) periodically for patients
receiving long-term opioid therapy, ranging from every prescription to every three months.

•

All long-term opioid therapy patients must sign or review an opioid treatment agreement and informed
consent form, which is placed in the medical record.

•

Providers use standardized forms and templates in the electronic health record (EHR) for managing
long-term opioid therapy patients.

•
•

Patients receiving long-term opioid therapy have urine drug tests every 12 months.

•
•

The practice will educate and engage the patient in order to ensure effective pain management.

The practice will not refill lost or stolen opioid prescriptions except in extraordinary circumstances.
A standard advance notification period (e.g., 4 days) prior to receiving an opioid refill is required.
A standard monthly refill will be for 28 days, so refills can be picked up on the same day of the week,
avoiding refills that fall on a weekend.

Providers must assess the functional status, quality of life, and pain intensity in all patients receiving
long-term opioid therapy at baseline and follow-up visits, using a standard scale (e.g., PEG).
Patients receiving long-term opioid therapy are expected to concurrently use nonopioid therapies and
self-care management strategies to increase engagement in life activities and enhance quality of life.
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Toolkit Part C.

Treatment Agreements
▶ The following are potential talking points to discuss with patients as part of the treatment agreement
conversation:

•
•

Discuss that opioid therapy at any dosage level carries potential risks as well as benefits.

•

Ensure the patient understands the practice’s policies regarding prescribing, refills, and use of different
prescribers and pharmacies.

•

Discuss the methods and reasons for monitoring the patient’s opioid use by means of UDTs, periodic v
isits, checking the state’s PDMP, and asking about symptoms of OUD. Assure the patient this is done for
the sake of their safety.

•

If needed, introduce the patient to others on the care team and describe what their roles and
responsibilities will be.

•

Conclude by summarizing the main responsibilities the provider and the patient will have.

Discuss that opioid therapy may not improve pain or function, and initial benefits may diminish
with prolonged use.

▶ The following are examples of treatment agreements for opioid therapy, followed by a health literacyappropriate treatment agreement:

•
•

Washington State Treatment Agreement (http://www.lni.wa.gov/Forms/pdf/F252-095-000.pdf)

•

Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain (http://
nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_b_v5_6.pdf) “Appendix B-5:
Sample Opioid Medication Treatment Agreement”

•

Treatment Plan Using Prescription Opioids (http://health.utah.gov/prescription/pdf/guidelines/
treatment_plan.pdf)

•

University of Michigan Health System Managing Chronic Non-Terminal Pain in Adults Including Prescribing
Controlled Substances (http://www.med.umich.edu/1info/FHP/practiceguides/pain/pain.pdf) “Appendix C.
Patient-Provider Agreement for Ongoing Use of Controlled Medication”

•

Oregon Pain Guidance (http://www.oregonpainguidance.org/app/content/uploads/2016/05/Patient
Treatment-Agreements.pdf) “Patient Treatment Agreement (Sample 3)”

VVA/DoD Clinical Practice Guideline Opioid Therapy: Chronic Pain Sample Opioid Pain Care Agreement
(https://www.nhms.org/sites/default/files/Pdfs/OpioidTxAgreement-VA2010.pdf)
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Example of a Treatment Agreement
Patient name: __________________________________

MR#:__________________________________

[Name of Clinic]
Pain Medicine and Other Controlled Substances Agreement
This agreement is for patients who are prescribed certain pain medicines called opioids and other “controlled
substances.” These medicines are sometimes called narcotics.
This agreement pertains to the following list of your medicine(s).

1
2
3
4
The purpose of this agreement is to describe how you, your physician, and your treatment team will work together to
make sure your medicine is used safely and works well to help you.
You and a [clinic] physician will sign the agreement to show you both understand and agree with it. It will be saved in
your medical record, so you and your treatment team can look at it again later. You will get a copy to take home.

My pain/symptoms and goals
My pain/symptoms is/are (describe):

What (activities) do I hope to be able to do?

Goals for me are (describe):

I understand the following:
F My pain/symptoms will probably not go away completely.
F My medicine may not work for me.
F The long-term use of opioid pain medicine is controversial.
F It is important not to miss appointments with my physician.
F Treating pain/symptoms often includes physical therapy, counseling, and/or other treatments.
F I will try additional treatments that my physician suggests.
F Increasing my participation in family, social, and/or work activities is part of my treatment program, which can

make pain less bothersome.
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Risks and safer use of controlled substances
Using this medicine might cause problems like:
F addiction

F allergic reactions

F breathing problems

F sleep apnea

F constipation and/or upset stomach
F dangerous driving and/or being charged with DUI
F feeling sleepy, dizzy, or confused
F overdose or death—especially if taken with alcohol or other drugs, or if I take more than my doctor prescribes
F problems urinating, problems with erections, reduced testosterone levels
F worse pain or feeling sick if I stop my pain medicine suddenly

I will:
F only get my medicine from my physician, Dr.________________, or a covering doctor at this office if my physician

is not available. If any other physicians prescribe pain medicine or other controlled substances for me in an
emergency, I will let my [clinic name] physician know as soon as possible.
F call my nurse, ______________, between the hours of 9 a.m. to 5 p.m. Monday through Friday with any questions

or concerns about my pain/symptoms or medications.
F only get the medicine(s) listed here from one pharmacy:____________________

Phone number: ___________________

I will:
F be honest and open with my physician and members of my treatment team about medicines and drugs I am

taking, including over-the-counter medications and illegal drugs.
F talk to my physician if I feel I need more medicine than was prescribed, but I will not change it on my own or take

pain medicine from other people.
F talk to my physician if I stop or would like to stop the medicine(s) listed here.
F never give or sell any of my medicine to anyone else.
F always keep my medicine in a safe place AND away from children and other people who come to my home.
F allow my doctor to check my urine to see what medicines or drugs I am taking.
F bring all of my unused medicines in their pharmacy bottles to my office visits if my doctor asks me.
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My physician will:
F work with me to find the best treatment for my pain/symptoms.
F be honest and open with me about my pain/symptom treatment.
F ask me about problems caused by my medicine and treat these effects.
F make sure my medicine is refilled on time.
F refill my medicine during a visit.
F allow my nurse to refill my medicine if I don’t have a scheduled appointment, and I will call at least 4 days before I

run out of medicine.
F arrange for a covering physician at the clinic to refill my medicine when my physician is not available.
F will not provide extra refills if my medicine or prescription is lost, stolen, destroyed, misplaced, or if I run out earlier

than expected.

Stopping and changing medicine (should involve provider-patient partnership and consent):
F My physician will stop or change my medicine if:

•
•
•

my goals are not being met, OR
I do not follow this agreement, OR
my physician thinks my medicine may be hurting me more than it is helping me.

F My physician might refer me to a specialist for treatment of pain/symptoms or drug problems.
F If my physician believes I have stolen or forged prescriptions, I sell my medicine, or if I threaten or act violently in

any way, I will no longer be prescribed controlled substances from this clinic.

I have been able to ask questions about this agreement, and I understand and agree with what it says.
Patient signature:

Date:

Physician signature:

Date:

Source: Adapted from a form used with permission of Dr. Jessica Merlin, Assistant Professor, Division of Infectious Diseases,
Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham.
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Toolkit Part D.

Telemedicine Consultation
Telemedicine consultations have been a way for healthcare providers without ready access to experts in a specific
clinical area can connect providers with those experts across the country and obtain provider-to-provider feedback
on specific patient cases. The following are two specific telemedicine consultation initiatives.

Project ECHO
“Project ECHO exponentially increases access to specialty care by moving knowledge,
instead of moving patients.” (http://echo.unm.edu)
Project Extension for Community Healthcare Outcomes (Project ECHO) was developed by the University of New
Mexico with the goal of breaking down the walls between specialty and primary care. It focused on creating
“communities of practice,” building primary care providers’ expertise, improving patients’ access to specialty care,
and improving the retention of primary care providers in rural and underserved communities. The development of
Project ECHO was sparked by the fact that thousands of people are unable to access appropriate specialty care for
their complex health conditions merely because there are not enough specialists to treat everyone who needs care;
the gap between the need to access specialty care and the ability to access specialty care is even more pronounced
in isolated and underserved communities. Project ECHO reduces these health disparities and revolutionizes medical
education and care delivery by training primary care physicians on how to provide these specialty services. As a
result, “primary care doctors, nurses, and other providers learn to provide excellent specialty care to patients in their
own communities” and are consequently able to treat patients they otherwise would have referred out (http://
echo.unm.edu). Initially launched so primary care providers could treat hepatitis C in their own communities,
Project ECHO has been expanded to address 11 different disease conditions, including chronic pain and headache
management.
The foundation of the Project ECHO model is its hub-and-spoke knowledge-sharing networks. These networks
are led by teams of experts who use multipoint videoconferencing to conduct virtual clinics with community
providers. Expert specialist teams at an academic hub are linked with primary care providers in local communities,
who represent the spokes. The model orients itself around a learning community, where information exchange is
multidirectional—“community providers learn from specialists, they learn from each other, and specialists learn from
community providers as new best practices emerge” (http://echo.unm.edu).

▶ Pain and opioid-specific teleECHO clinics
Expert specialists and primary care providers participate in weekly TeleECHO clinics, which resemble virtual grand rounds and
are combined with mentoring and patient care presentations. “The Chronic Pain & Headache TeleECHO Clinic (ECHO Pain)
facilitates a multifaceted approach to chronic pain by incorporating a team of specialists that support primary care providers
in rural communities who lack the resources necessary to sufficiently understand the management of [chronic] pain.”

•

The University of New Mexico: Project ECHO was developed by the University of New Mexico and launched
in 2003. Specialist teams at academic medical centers throughout the state are linked to local providers.
There are more than 45 sites receiving medical education and care management training with a treatment
focus of “Chronic Pain and Headache” within the state of New Mexico. (http://echo.unm.edu/)

•

The Integrative Pain Center of Arizona: The Integrative Pain Center of Arizona (IPCA) and its partner, the
Community Health Clinic, Inc. (CHC) conducted the first Project ECHO replication project in Arizona and
Connecticut. This is known as the CHC-IPCA ECHO. The Weitzman Institute is a branch of the Community
Health Center, Inc. It is the first community-based research center established by a Federally Qualified
Health Center. The Institute uses weekly Project ECHO telemedicine conferences to connect primary care
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providers with expert faculty and improve the management of chronic pain.

•

Project ECHO was introduced to the Department of Veterans Affairs (VA) in 2010. “Specialty Care Services
adopted and expanded this program to transform the delivery of specialty care throughout VA. Specialty
Care Access Network-Extensions for Community (SCAN-ECHO) extends the reach of specialty services
and coordinates with the Veterans Patient Aligned Care Team (PACT).” (http://www.va.gov/HEALTH/docs/
Specialty-Care-Access-Network.pdf)

•

“The Rural Opiate Addiction Management Project for Rural Washington Physicians (Project ROAM) trains rural
physicians in opioid use and helps them apply for the waiver to legally prescribe buprenorphine. After Project
ROAM trains providers, Project ECHO’s interdisciplinary experts monitor them as they begin to treat addiction in
their practices.” (http://depts.washington.edu/givemed/magazine/2011/03/addiction-and-chronic-pain/)

University of Washington TelePain (UW TelePain)
UW TelePain multidisciplinary pain expert tele-mentoring has already successfully demonstrated an effective means
to disseminate and implement guidelines for prescribing opioids for chronic pain (Washington State Agency Medical
Director’s Group Interagency Guideline on Prescribing Opioids for Pain ) across a large regional network (Washington
State, Wyoming, Alaska, Montana, Idaho, Oregon, and Colorado) of primary care providers. Since March 2011, a
multidisciplinary team of pain experts has delivered to more than 7,300 total attendees > 10,500 hours of chronic pain
training, education, and consultation (30 avg./session, unique attendees 1,200+), reaching out to 270+ unique locations.3
Launched in direct response to extremely poor access to pain specialists, and confronting statewide high opioid
use and escalating dose, with poor patient outcomes and “distressed” primary and specialty care practices , the
Washington State legislature instructed the WA State Department of Health to impose 2011 regulatory requirements.
These requirements necessitated access to pain specialty consultation for patients who met one or more of these
criteria: on high-dose opioids, have poor pain outcomes, or are at high risk of addiction.

▶ Didactic curriculum (repeats every six months)
•
•
•
•
•
•
•
•
•

Pain history and assessment
Motivational interviewing
Functional assessment
Addiction assessment
Establishing a pain diagnosis
Risk screening for opioid safety
UDT: use, interpret, respond
Opioids and MME calculation
Controlled substance agreements

•
•
•
•
•
•
•
•

Prescription drug monitoring programs: how to
access, use, and respond
Pain tracker: patient outcomes
Adjuvant analgesics
Anxiety: assessment and treatment
Depression: assessment and treatment
PTSD as comorbid condition: assessment and treatment
Cognitive-behavioral therapy
Exercise and pain

▶ Supplemental curriculum (repeats every year)
•
•
•
•
•
•

Medicinal cannabis
Methadone
Sleep disturbances and chronic pain
Disability
Complementary and alternative
medicine
Pain in children

•
•
•
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Pain in older adults
Pain during pregnancy
Primary care pain disorders (e.g., fibromyalgia,
headaches, osteoarthritis, low back pain,
diabetic peripheral neuropathy, visceral
abdominal and pelvic pain)
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Toolkit Part E.

Examples of Training Resources
▶ The following table describes existing resources for training on the

topics relevant to safer and more effective management of long-term
opioid therapy in non-cancer pain patients. The table provides the URL to
access each training and indicates the topics covered by each resource.
CDC Clinician Outreach and Communication Activity
(COCA) Calls/Webinars: CDC’s National Center for Injury Prevention and Control (NCIPC) partnered with CDC’s
Clinician Outreach and Communication Activity (COCA) and the University of Washington to present a webinar
series about the CDC Guideline for Prescribing Opioids for Chronic Pain. This seven-part series is intended to
use a data-driven approach to help providers choose the most effective pain treatment options
and improve the safety of opioid prescribing for chronic pain. The primary objective is to provide informative,
case-based content that will demonstrate and instruct participants on how the 12 recommendations of the
the CDC Prescribing Guideline can be incorporated and applied in a primary care practice setting.

•

CDC’s seven-part COCA Call Webinar Series

CDC’s Online Training Series for Healthcare Providers: This interactive online training series aims to help
healthcare providers apply CDC’s recommendations in clinical settings through patient scenarios, videos,
knowledge checks, tips, and resources. Providers can gain a better understanding of the recommendations,
the risks and benefits of prescription opioids, nonopioid treatment options, patient communication, and risk
mitigation. Additional topics are planned. Each stand-alone module is self-paced and offers free continuing
education credit (CME, CNE, and CEU).

•

Applying CDC’s Guideline for Prescribing Opioids Online Training Series

Additional resources:

•
•

CDC Train
CDC Learning Connection

Select educational resources for providers
▶ The following are resources that can be used in training providers and other healthcare
professionals to support care coordination of long-term opioid therapy:

•

Group Health Research Institute’s “Principles for more selective and cautious opioid prescribing”
(https://depts.washington.edu/anesth/education/forms/pain/Principles_opioidPrescribing.pdf)

•

Deyo, Von Korff and Duhrkoop’s state of the art review of opioids. See: Deyo, R. A., Von Korff, M., & Duhrkoop,
D. (2015). Opioids for low back pain. Bmj, 350, g6380. (http://www.bmj.com/content/350/bmj.g6380)

Additional resources:

•
•
•
•

Safe and Effective Opioid Prescribing for Chronic Pain (Boston University School of Medicine)
Prescriber’s Clinical Support System for Opioid Therapies (PCSS-O)
Prescriber’s Clinical Support System for Medicated Assisted Treatment (PCSS-MAT)
COPE-REMS (University of Washington)
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Toolkit Part F.

Challenges or Barriers to Implementing Long-term Opioid
Management Strategies and Potential Solutions
▶ Table 1. Solutions for implementing long-term opioid management strategies
CHALLENGES OR BARRIERS

POTENTIAL SOLUTIONS

Lack of provider understanding of the safety issues with
long-term opioid therapy and extent of misuse and abuse.

Provide training to providers; retrain and update on findings in practice
(e.g., rates of misuse).

Insufficient access to needed patient information.

Use strategies like the Prescription Drug Monitoring Programs (PDMPs)
and other sources mentioned in CDC Prescribing Guideline.

Competing demands on providers’ time.

Educate practices and providers on the real safety issue with long-term
opioid therapy and the importance for providing high-quality care.

Inadequate time for providers to participate in telemedicine
or e-consulting (Project ECHO).

Encourage medical directors to prioritize ongoing training, support,
and provider participation in telemedicine efforts.

Insufficient provider adherence to new opioid policies

Have the leadership provide incentives

Challenges with applying policies or strategies because of
the difficult conversations to hold with patients.

Provide robust training on difficult conversations with patients in
managing long-term opioid therapy.

Consistency across providers’ approaches to assessment,
care plan, documentation.

Create templates embedded in the EHR (e.g., treatment agreement,
pain assessment components).

Excessive number of calls from patients demanding
medication renewals and other requests.

Develop a treatment agreement to set consistent response to calls and
demands from patients.
Designate a person who has a list of patients on opioids—print out
prescription for provider to sign (after ensuring that the patient has a
follow-up scheduled within 3 months of last evaluation).

Unknown prejudice and bias against patients who develop
opioid addiction among staff.

Address prejudice and bias at the beginning of implementation and as
part of training to enhance non-judgmental interviewing skills of providers.

Limited uptake and utilization of standardized templates for
documentation.

Use a clinical dashboard or other monitoring tool to share each
provider’s rates.

Use a team-based approach to leverage providers’ time, and provide a
Providers “got no time for pain,” as one leader in long-term opioid
template of aspects to cover in pain assessment to support the providertherapy described it. Providers have inadequate time to discuss
patient encounter. Use other staff to do tasks that they can (e.g., print
with patients about their pain.
PDMP results, order UDT per protocol).
Inefficient work procedures or workflow to implement
some strategies successfully.

Determine the appropriate workflow for staff in their role implementing
the strategies is important (e.g., understanding who, how, and when
random UDTs will be drawn).

Some PDMP systems are clunky; a non-delegable duty
to check; difficulty to register on system.

Many states are making improvements to their PDMP systems; New Jersey
developed an app to access their PDMP. Health systems can work with EHR
vendors to integrate PDMP information into the EHR.

Inconsistent implementation; providers do not complete
or integrate all components.

Create EHR templates and monitor progress and rates of adherence
to policy.

Adhering to templates for assessment or monitoring
long-term opioid therapy /pain.

Use clinical dashboard to closely monitor and display utilization by
provider and make the dashboard publicly visible and available; providers
can see ratings of themselves and other providers—incentive not to be an
outlier with poor adherence to templates (negative incentive).

Limited resources.

Leverage existing infrastructure (i.e., EHR, QI), utilize staff to the top of their
licenses (e.g., MAs), and select strategies that are appropriate and feasible
given current resource constraints.
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Toolkit Part G.

PEG: Scale to Assess Pain Intensity and Interference
▶ The PEG is a three-item scale to assess pain intensity and interference.
1. What number best describes your pain on average in the past week?

0

1

2

3

4

5

6

7

8

9

No pain

10
Pain as bad as
you can imagine

2. What number best describes how, during the past week, pain has interfered with your enjoyment of life?

0

1

2

3

4

5

6

7

8

9

Does not
interfere

10
Completely
Interferes

3. What number best describes how, during the past week, pain has interfered with your general activity?

0

1

2

3

4

5

6

7

8

Does not
interfere

9

10
Completely
Interferes

Source: Krebs EE, Lorenz KA, Bair MJ, et al. Development and Initial Validation of the PEG, a Three-item
Scale Assessing Pain Intensity and Interference. J. Gen. Intern. Med. 2009;24(6):733-738

79

Quality Improvement and Care Coordination

CDC National Center for Injury Prevention and Control | 2018

Toolkit Part H.

Nonopioid Options for Managing Chronic Pain
▶ CDC resources:
Fact Sheets:

Training:

•

Nonopioid Treatment
for Chronic Pain

•

Promoting Safer and
More Effective Pain
Management

•

Treating Chronic Pain
Without Opioids

▶ Table 2. Nonopioid options for managing chronic pain
Patient lifestyle

•
•
•
•
•
•

•

•
•

•

Increasing engagement in meaningful,
rewarding and/or pleasant life activities
that reduce focus on chronic pain
Healthy sleep management including sleep
restriction and stimulus control techniques
Weight reduction
Improve healthy eating and nutrition
Stress reduction, relaxation, mindfulness
meditation
Exercise (including non-aerobic, low impact
activities that reduce sedentary time lying
down or sitting)

Behavioral interventions

•

Physiotherapy interventions
Functional therapies
- Physical therapy (PT)
- Occupational therapy (OT)
- Passive modalities (“activities performed by the
physical therapist on the patient without any form
of exercise involving patient volitional efforts”)

Medical interventions

•

Educational groups
- Preventive
- Support
- Peer-to-peer/Living well workshops
- Shared medical appointments
Psychotherapy
- Individual counseling
- Group therapy
- Cognitive behavioral therapy
- Acceptance and commitment therapy

•

Supportive care
- Case management

•

Trauma-informed care
- PTSD screening
- Domestic violence screening
- Child abuse screening

Nonopioid medications that may aid in chronic pain
management

-

NSAIDS, acetaminophen
Tricyclic antidepressants (neuropathic pain)
Anti-epileptics (neuropathic pain)
Antidepressants
Topical medications

Minimally invasive surgical procedures
- Nerve blocks, steroid injections
- Interventional treatments: ablations, injections,
- Surgical treatment
Complementary and alternative treatments
- Manipulation therapy

Source: Oregon Pain Guidance Group. Opioid Prescribing Guidelines. Oregon Pain Guidance. 2014.
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Toolkit Part I.

Additional Guidance on Urine Drug Testing
Who should be tested?
All patients on long-term opioid therapy should have UDTs periodically. Patients can be targeted for testing based
on the risk of abuse or be selected randomly, though implementing random testing can be difficult for practices. 4-11
Universal testing similar to universal precautions is another approach that aims to “de-stigmatize” testing and to
remove any perceived bias related to patients selected for testing. 1-4, 6-7, 13-16

Key points to provide patients before conducting UDT
▶ Discuss the following key points regarding UDT with the patient beforehand:
• Purposes of testing.
• Provider/patient trust—requiring UDT does not imply a lack of trust on the part of the provider;
it is part of a standardized set of safety measures.

•
•
•
•
•
•
•

What drugs the test will cover.
What results does the patient expect?
Prescribed drugs or any other drugs (including marijuana and other illicit drugs) the patient has taken.
Time and dose of most recently consumed opioids.
Potential cost to patient if the UDT is not covered by insurance.
Expectation of random repeat testing depending on treatment agreement and monitoring approach.
Actions that may be taken based on the results of the test.

Interpreting results and actions to be taken
Providers need to be aware of the limits of UDTs and have a resource for questions regarding drug testing or
results.12 This could be a certified medical review officer, clinical laboratory director, or manufacturer for point
of care (POC) testing.10 Multiple variables affect the diagnostic accuracy of UDTs, including cutoff selection,
pharmacokinetics, pharmacodynamics, and pharmacogenetics, laboratory technology, and subversion or
adulteration of the urine specimen.3-4, 16

¹ Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages
for clinical practice? Pol Arch Med Wewn. 2009;119(7-8):469-477
² Chou R, Deyo R, Devine B, et al. The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain. Vol Evidence Report/Technology Assessment No. 218. Rockville, MD: Agency for Healthcare
Research and Quality; 2014.
³ Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 1 - Evidence assessment.
Pain Physician. 2012;15:S1-S66.
4 Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - Guidance. Pain Physician.
2012;15:S67-S116.
5 National Opioid Use Guideline Group (NOUGG). Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. 2010.
6 Chou R, Fanciullo GJ, Fine PG, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain. 2009;10(2):113-130.
7 Hooten WM, Timming R, Belgrade M, et al. Institute for Clinical Systems Improvement. Assessment and Management of Chronic Pain. 2013.
8 Thorson D, Biewen P, Bonte B, et al. Institute for Clinical Systems Improvement. Acute Pain Assessment and Opioid Prescribing Protocol. 2014.
9 The University of Michigan. Managing Chronic Non-Terminal Pain Including Prescribed Controlled Substances. Guidelines for Clinical Care. 2009.
1⁰ Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain. The Management of Opioid Therapy for Chronic Pain
Working Group. 2010.
11 Washington State Agency Medical Directors’ Group. Interagency Guideline on Prescribing Opioids for Pain 2015.
12 Agency Medical Directors Group (AMDG). Interagency Guideline on Opioid Dosing for Chronic Non-Cancer Pain: An educational aid to improve care and safety with opioid therapy. 2010.
13 Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert ASB. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. 2015;350.
14 Degenhardt L, Bruno R, Lintzeris N, et al. Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a
cohort study. Lancet Psychiatry. 2015;2(4):314-322.
15 Timm KE. A randomized-control study of active and passive treatments for chronic low back pain following L5 laminectomy. Journal of Orthopaedic & Sports Physical Therapy. 1994;20(6):276-286.
16 Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14:123-143.
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Unexpected UDT results, interpretation, and options
for providers’ response
▶ Table 3. Unexpected results, possible explanations, and potential actions for providers to take
Unexpected result
UDT negative for
prescribed opioid

Possible explanation

•
•
•

Actions for provider

•

False negative.
Non-compliance.
Diversion.

•
•
•

UDT positive for nonprescribed opioid or
benzodiazepines

UDT positive for illicit drugs
(e.g., cocaine, cannabis)

•
•

•
•
•

Urine creatinine is lower than
2-3 mmol/liter or
< 20 mg/dL

•

False positive.
Patient acquired
opioids from other
sources (double
doctoring, “street”).
False positive.
Patient is occasional
user or addicted to
the illicit drug.
Cannabis is positive
for patients taking
dronabinol (Marinol).
THC: CBD (Sativex)
or using medical
marijuana.
Patient added water
to sample.

•
•
•
•
•
•
•

•
•
•
•

Urine sample is cold

•
•

Delay in handling
sample (urine cools
within minutes).
Patient added water
to sample.

•
•
•
•

Repeat test using chromatography: specify the
drug of interest (e.g., oxycodone often missed by
immunoassay).
Take detailed history of the patient’s medication
use for the preceding 7 days (e.g., could learn
that patient ran out several days prior to test).
Ask patient if they’ve given the drug to others.
Monitor compliance with pill counts.
Repeat UDT regularly
Ask the patient if they accessed opioids
from other sources.
Assess for opioid misuse/addition?
Review/revise treatment agreement.
Repeat UDT regularly.
Assess for abuse/addiction and refer for
addiction treatment as appropriate.
Ask about medical prescription of dronabinol,
Delata-9-Tetrahydrocannabinol (THC):
Cannabidiol (CBD) or medical marijuana access
program.

Repeat UDT.
Consider supervised collection or temperature
testing.
Take a detailed history of the patient’s
medication use for the preceding 7 days.
Review/revise treatment agreement.
Repeat UDT.
Consider supervised collection or temperature
testing.
Take a detailed history of the patient’s
medication use for the preceding 7 days.
Review/revise treatment agreement.

Source: National Opioid Use Guideline Group (NOUGG). Canadian Guideline for Safe and Effective Use of Opioids for Chronic
Non-Cancer Pain. 2010.
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Actions to take after UDT results
▶ Act on the UDT results in the following ways:
• Inform the patient of the test results.
• Discuss with the patient any unexpected results or findings of drug use that the patient had talked about
prior to the test. It can be helpful to ask patients what to expect the UDT will show beforehand.

•
•

Review the treatment agreement and reiterate concerns about the patient’s safety.
Determine if frequency and intensity of monitoring should be increased.

For additional information on using UDTs to monitor opioid therapy, see the Washington State Agency Medical
Directors’ Group’s Interagency Guidelines on Prescribing Opioids for Pain. (http://www.agencymeddirectors.wa.gov/
Files/2015AMDGOpioidGuideline.pdf).
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Toolkit Part J.

Tapering and Discontinuing Opioids
•

CDC’s Pocket Guide for Tapering Opioids for Chronic Pain
(https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf)

•

Dosing and Titration of Opioids
(https://emergency.cdc.gov/coca/calls/2016/callinfo_081716.asp)

•

“Tapering or Weaning Patients off of Chronic Opioid Therapy”
(https://7cd526d7dc73a4cc6c93-d371975f3074159d211824381bcd2df5.ssl.cf1.
rackcdn.com/GroupHealthTapering_Patients_off_Chronic_Opioid_Therapy.pdf)

•

Tapering Long-term Opioid Therapy in Chronic Noncancer Pain: Evidence and
Recommendations for Everyday Practice. Mayo Clin Proc. 2015;90(6):828-842.
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Toolkit Part K.

Working Collaboratively with Patients Receiving
Long-term Opioid Therapy: Principles and Examples
▶ CDC resources:

•
•
•
•
•
•

Guideline resources: CDC Opioid Guideline Mobile App
Training: Communicating with Patients
Checklist: PDO Checklist for Prescribing Opioids
Brochure: Pharmacists on the Front Lines
Fact sheet: Prescription Drug Monitoring Programs
Pocket guide: SAMHSA Pocket Guide for Medication-Assisted Treatment (MAT)

Use these principles and language suggestions when discussing with the patient, opioid risks and safety
monitoring or introducing a change in treatment plan.

Principles for talking with patients about opioids
Keep the primary focus on outcomes patients care about.

•

Conversations should focus on improving overall quality of life, enabling participation in important life
activities, protecting patients from opioid-related harm, and achieving their long-term goals, not on
eliminating pain. Emphasize concern for the patient’s well-being.

▶ When discussing risk, focus on the medications.
• Make it clear that drug-related harms can happen to anyone, so all patients are monitored for signs they
are having problems with opioids.

•

Emphasize that new information on opioid risks and harms are leading providers to change when and
how opioids are prescribed.

•

Particularly if patients are prescribed moderate-to-high opioid doses or are using other sedating substances
(sedatives, alcohol), discuss risks of opioids suppressing respiratory drive.

•

Particularly if patients have a history of substance abuse disorder, discuss risks of opioids inadvertently
endangering their sobriety.

▶ Develop a differential diagnosis for patient behaviors that cause concern.
• If a patient is misusing opioids, expressing concerns about opioid effects, reports symptoms of OUD

when asked relevant questions, getting opioids from multiple sources, using more than prescribed, or
has unexpected urine results, consider it a sign of potential opioid-related harm or an unrecognized
serious condition (e.g., substance use disorder, depression)—not as a “treatment agreement violation.”

•

When deciding on treatment changes, consider all evidence you have about the benefits and harms
the patient is experiencing.
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▶ Focus on what patients can do to improve their quality of life.
• Opioids are not a “panacea” and should not be the main approach to managing chronic pain. On average,
patients can expect a 30 percent reduction in pain at 12 weeks, but long-term benefits for pain relief are
unknown. Initial analgesic benefits may not be sustained long term.

•

Instead, help patients explore ways to live better and become more engaged in life activities—the ability to
do more of what the patient values most. Have patients define treatment goals without using the word “pain.”
Alternatively, ask what they would be doing if they had less pain.

•

Options to increase activities that patients have more control over than pain can be more effective over the
long run and carry fewer risks than prescriptions for pain medications.

•

Even with chronic pain, many patients can go for walks or do other pleasant activities that reduce their
suffering. Emphasize the importance of using multiple therapies and self-care strategies in addition to
using opioids.

•
•

Help address any unrealistic anxieties or fears patients may have about physical activity.

•

Emphasize the potentially temporary nature of pain relief from opioids—but the permanent dependence on
opioids—to avoid withdrawal symptoms. Over time, it can be difficult to distinguish benefits of pain relief
from the avoidance of withdrawal symptoms.

•

Remember that your relationship with and empathy for the patient, along with optimism that your patient
can achieve a better quality of life, are the most important things you offer, not the drugs, tests, and
procedures you prescribe.

If a patient asks for a higher dose, redirect the conversation to strategies more likely to improve their quality
of life in the long run.

Effective patient communication and education
In high-quality care for chronic pain, the provider’s relationship with the patient can be much more important
than the drugs, tests, or procedures prescribed.

▶ Remember the importance of the patient-provider relationship.
• It is important to work collaboratively with patients, conveying empathy for the difficulties living with

chronic pain, and adopt a non-judgmental stance. Communication with the patient is a building block of
the therapeutic relationship. Emphasize the shared goal of ensuring safety and improving quality of life,
while acknowledging the patient’s own experiences with the limitations of medications for controlling
chronic pain. During pain exacerbations, help the patient recall that pain will improve and identify temporary
management strategies (pharmacologic or otherwise) rather than escalating opioid dose for the long run.
Remember, what the provider says is only part of what is being communicated. Body language, eye contact,
and expressions of respect and empathy send messages that engender trust. Because long-term opioid
therapy is inherently risky, patients’ trust in their providers is essential to safe and successful treatment.

▶ Use a patient-centered, empathic communications style.
• Some conversations with patients treated for chronic pain are difficult for both providers and patients.
▶ Use suggested approaches to working collaboratively with patients when dealing with difficult and
sensitive issues:

•
•
•
•
•
•

Introduce the changes being made in the practice to manage long-term opioid therapy.
Introduce the need for monitoring.
Discuss patient preferences regarding dose-reduction or tapering.
Introduce non-drug approaches to managing chronic pain.
Discuss refills and irregularities in supply of medications.
Respond to unexpected findings in UDT or PDMP.
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▶ Talk with patients about UDT.
▶ Review the model approaches for working with patients through difficult situations and consider adapting
the suggested language to your practice.

•

Providers can also utilize education resources to help patients understand the risks, develop realistic
expectations regarding the long-term effectiveness of opioid therapy and the limited scientific evidence,
and better understand the many different ways of managing chronic pain that some patients find helpful.

▶ Use patient education resources to help patients understand the risks of opioid therapy and different ways
of managing chronic pain that patients find helpful.

•

(See Toolkit Part L for a list of existing patient education resources.)

Having difficult conversations
▶ Introducing a change in practice1 (Krebs et al.)
“I want to talk with you about how what we know about opioids has changed based on the
latest science and clinical recommendations.”
“Fifteen years ago, many physicians were taught that these medications were good for most
kinds of pain and almost risk free. But recent evidence has shown us they were wrong.”
Focus on new information
and how expert thinking on
opioids has changed.

“Have you been paying attention to the news about pain meds lately? Do you have concerns
or questions about what you’ve been hearing?”
“From what you have been telling me, these medications aren’t as effective as you would like.
Let’s think about trying something different.”
If patient is defensive: “Patients who expect drugs alone to improve their overall quality of life
are usually disappointed. What are other things you do that seem to help you be more active?
Let’s talk about approaches that I have seen work for other patients with problems like yours.”

▶ Introducing monitoring for opioid harms (Krebs et al.)
“These drugs have serious risks even when used as directed, especially at higher doses.”
For patients on higher doses, using extra for flare-ups, or using sedatives and/or alcohol:
"These drugs can stop your breathing which can cause you to die. It happens even when people
have been on the same dose for a long time.”
Focus on the harms
opioids can cause.

“We used to think people suffering from pain did not become addicted to prescription pain medicines.
We now know that you can become addicted to pain killers used for chronic pain, even if you haven’t
had problems with drugs or alcohol in the past.”
“We used to think the dose didn’t matter as long as we went up slowly, but now we know higher doses
lead to higher risks of serious injuries and accidental death. And, higher doses don’t seem to reduce
pain over the long run.”

1 Krebs E, Von Korff M, Deyo R, et al. Safer Management of Opioids for Chronic Pain: Principles and language suggestions for talking with patients.
Minneapolis: Center for Chronic Disease Outcomes Research, Women’s Veteran’s Comprehensive Health Center
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“Our clinic has a policy recommending against moving to higher doses because there is no evidence of
benefits, but risks and harms are much greater, and it can be much harder to quit if problems arise.”
Reduce stigma by treating
everyone the same.

“Our clinic is making changes for all of our patients, so pain medication prescribing is safer than it has
been in the past.”
“It’s my job to consider potential benefits and harms and prescribe treatments only when they are safe
and the benefits are greater than the potential harms.”
“Our clinic suggests monitoring opioid safety using standard approaches for all patients.”
“People don’t choose to develop an addiction, and I have no way to predict who might have trouble
with these medications.”

Be your patient’s ally
by expressing empathy and
support for their concerns
and uncertainties.

“Do you know anyone who has had an opioid problem, such as becoming addicted, or been hurt by
these medications, such as an overdose?”
“I promise to be honest with you if I have any concerns about how you are using your medications. In
turn, I ask you to let me know right away if you develop any cravings or other concerns about how the
drugs are affecting you. It is common to experience these problems, and they aren’t your fault, so let me
know right away.”

▶ Introducing dose reduction or tapering (Krebs et al.)
“Some call them ‘pain killers,’ but they don’t work that well for most people with back pain. Studies
show that 4 out of 5 people continue to have bad pain and pain-related activity limitations when
using opioids long term.”
“My experience is that patients who taper opioids end up with clearer thinking and more energy
to engage in positive activities that help them focus less on their pain.”

Provide information
and redirect the
conversation.

“It seems the body just gets used to the long-acting, around-the-clock medicines, and they quit
working. Many of my patients seem to do better taking the short-acting medications only when they
need them.”
“For most people, the benefits wear off as the body gets used to the medications. Then they’re stuck on
a medicine that isn’t really doing much for them. They often assume they’d be worse off without it, but
it turns out that’s not true. Let’s talk about what you can do to live a better life, so all your eggs aren’t in
one basket.”
“These drugs have risks for everyone who takes them. You are more likely to have a serious harm
because you [have been taking them for a long time; are taking them every day; are taking > 50 mg
morphine equivalent dose a day; are taking sleeping pills, too; have a family history of alcoholism; have
depression; etc.]. We can’t do much about your family history, but you could reduce your risk by [going
down on the dose; stopping the sleeping pills; taking them less often].”
“Do you ever worry about harmful effects of your pain medications?”

Ask about the
patient’s concerns.

“You’re on a very high dose and have been for [number of ] years. Do you ever wonder if the drugs are
still working for you?”
“How would you feel about taking these medications for the rest of your life?”
“Have you ever thought about trying to cut back?”
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“You’re telling me that your pain is really terrible, and I hear you. It seems to me that what we’re doing
just isn’t working. I know they helped you at first, but I think the effect of the medications has worn off.
We should consider making some changes.”
“I wonder if you really need to be on this high a dose. In my experience, most people can cut their doses
back quite a bit without any increase in pain. I’d like to try going down just [5 mg; 1 pill a day; etc.] and
see if you notice a difference. What do you think?”
Suggest a change.

“I want to start making changes to make sure this medication is safe for you. There are several different
things we could start with … [provide options]. Where would you like to start?”
“While we’re working on the medications, I also want to work on some of the underlying things that are
contributing to your pain. For you to get better, you’ll need to [get stronger; start being more active; get
back to your social life]. I’d like to talk about some goals we can keep track of together, so we know how
well our plan is working.”

Continually revisit
readiness to change.

“Last time, we talked about [the safety of your pain meds; whether the opioids are really working]. I still
recommend [making some changes; going down on the dose]. Have you thought more about whether
you’re ready for that?”
If yes, suggest options. If no, remind of reasons, suggest potential options, ask again next visit.
“We can push the pause button any time you need to.”
“I don’t want to make any sudden moves—just one baby step at a time. Then we’ll talk about
the results together.”
“I promise I’m going to stick by you.”

Be honest and reassuring about
what patients can expect.

“Remember, you might feel a little worse before you feel better. I want to see you again in four weeks
to check how you’re doing. By then, your pain should be evened out again.”
“Since your body is used to having this drug in your system, you might feel withdrawal symptoms after
we decrease your dose. This might mean you feel more pain or get worse sleep. But it will be temporary.
It doesn’t mean the drug is actually helping—it’s just that your body needs to get used to the new dose.”
“As a back-up plan, in case of a seriously bad day, I could give you some extra [short-acting opioid].”

Be honest and reassuring about
what patients can expect.

When tapering after a small dose reduction, ask the patient about any positive changes—such as increased
energy, alertness, ability to be active, sleeping better. It helps to have patients focus on any beneficial out
comes. It may also be helpful to note expected negative effects that did not materialize:
“From what you are saying, your pain seems to be about the same as before.”
“Remember how miserable you were on the medications? If your pain was really well-controlled back
then, we wouldn’t be doing this at all.”
“Let’s just hold on the current dose and not try to make more changes right now. How are things going
with your goal to [walk every day; keep a regular sleep schedule; join the gym]?”
Focus on ways to problem-solve and reach the patient’s goals.

Respond to setbacks and focus
on problem-solving.

“Usually these flare-ups only last a few days. Is there anything that would help to take your mind off it in
the meantime? I know you mentioned that [you do better when you’re with other people; that it feels
good to float in the pool].”
“I’m not holding out on you. If I had an easy solution for the pain today, I’d give it to you right now.
I still think this is going to be worth it in the long run.’
Remind the patient of their long-term goals.
“How can you get back on track with [your short-term goal]?”
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▶ Introducing nondrug approaches to managing chronic pain (Krebs et al.)
Try giving a limited amount of reading material that will be discussed at the next visit. Information on sleep
and pacing are helpful for many patients.
“This workbook has helped other patients of mine with chronic pain. It gives a lot of different ideas for
ways to manage chronic pain”
Check in on progress at every visit, even if not discussed in depth:
Introduce materials on other
ways to manage chronic pain.

“How are things going with the relaxation techniques we talked about?”
“There are a lot of things that make pain worse, like not sleeping well, or doing too little or too much
exercise. When the pain is really bad, people do things that make it worse, like shallow breathing, tensing
muscles, and thinking that the pain will never get better. This provides a menu of options.”
Focusing discussion on these kinds of options can change the conversation from what the doctor is doing to
control pain to what the patient is doing to improve quality of life This can be helpful, even if the changes seem
small initially.

▶ Talking with patients about medication supply2 (SAMHSA, 2012)
Provider

“I see that you are here because you ran out of your pain medication before you were due to pick up
the next prescription.”

Patient

“I took extra pills for a few days, and now I’m out. I’m hurting more because I don’t have any pills.”

Provider

“Can you tell me what happened?”

Patient

“I fell and hurt my knee, and it was really bothering me, so I took more than I usually do.”

Provider

“We have a written agreement that you’ll take your medications only as prescribed.”

Patient

“Yeah, but it made sense because my knee hurt so bad.”

Provider

“Knee pain is a different kind of pain, and increasing your opioid medication is not necessarily the best
treatment for that. Next time, please call me first as we agreed.”

Patient

“OK, I’m sorry.”

Provider

“Whenever one of my patients breaks the agreement for any reason, I always ask for a urine sample.
When did you last take your medicine?”

Patient

“I just ran out yesterday.”

Provider

“So you did not take anything else when you ran out of your prescription?”

Patient

“No! I didn’t have anything else to take.”

Provider

“OK, I’ll write your prescription while you go see the nurse. If your urine sample is OK, I’ll give you
your prescription.”

▶ Responding to unexpected findings, UDT or PDMP results, or concern for substance use disorder
or diversion (Krebs et al.)

“I called because I’m concerned about you. There was something I didn’t expect in your
[urine/ pharmacy records], so I wanted to check in with you about how you’re doing.”
Keep the focus on the patient’s
well-being.

Followed by silence to allow patient to talk.
“This pattern can sometimes be a sign that a person is at risk for opioid addiction, which is a serious
disease that needs treatment.”
Followed by assessment questions and offer of resource/referral.
“It’s my job to weigh up the potential benefits and potential harms, and to prescribe medications only
when the benefits are greater than the harms. In your situation, I’m worried the risks outweigh the
benefits, so I can’t keep prescribing them for you.”

2 Substance Abuse and Mental Health Services Administration (SAMHSA). A Treatment Improvement Protocol: Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders. 2012.
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“I know that medications get lost and things happen. But this pattern can also look like there is a problem
developing—like someone is getting hold of your medicines, or there is loss of control over how much
you are using. As a doctor, I just can’t prescribe if I’m not 100% sure where the medications are going
and how they are being used.”
“As a doctor, my job is to be careful with these medications and to watch out for your health.”
“I’m not sure what’s been happening with you, but I’m concerned for your well-being.”
“These drugs aren’t an ideal treatment for pain in the long term, anyway. For many people, their effects
wear off over time. I’d like to try some new approaches to see if we can do better.”

Redirect the conversation while
maintaining the relationship.

“Patients who expect drugs to control their pain are usually disappointed. With or without chronic
pain, my patients who are doing better use multiple approaches. Let’s talk about what might help you
become more active and do more things that you enjoy [walking; pleasant activities; relaxing activities;
mindfulness meditation; avoiding thoughts that everyday pain means you are harming your body].”
It can be difficult to talk about alternatives if opioids are being cut off or reduced against the patient’s wishes.
In difficult circumstances, taking time to listen to concerns (within limits) and expressing empathy without
changing your decision can be helpful for the future.

Redirect the conversation while
maintaining the relationship.

“I want to work with you to find a better pain management plan.”
“When can you come back to see me?”

▶ Addressing resistance to urine drug testing (SAMHSA, 2012)
Patient

“Why do I need to give you a urine sample? Don’t you trust me?"

Provider

“The urine sample gives me a great deal of useful information about how you are using your medications
and whether you are running into problems with other substances.”

Patient

“It feels like spying.”

Provider

“It may seem like that to you, but it’s a standard part of care for all my patients. Any level of substance
use can affect a patient’s life and the management of the pain. I do this as part of my responsibility to
lower risks for all my patients, along with asking about your concerns. Is there something we need to
talk about?”

Patient

“But I gave you a urine sample last time I was here.”

Provider

“Yes, you did. Let’s look at the standard treatment agreement. Let’s see. Here it is. We agreed that
you might be asked for a screen at every appointment.”

▶ Talking with Patients about unexpected UDT results (SAMHSA, 2012)
Provider

“It seems you have been taking medications that I haven’t prescribed.”

Patient

“No, I haven’t.”

Provider

“Your last urine test was positive for benzodiazepines. Can you think of any reasons why they might
have appeared?”
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Toolkit Part L.

Patient Education Resources
▶ The following are examples of patient education resources:
• Fact Sheet: Prescription Opioids: What You Need to Know
• Patient Poster: Expectations for Opioid Therapy
• Video: Prescription Opioids: Even When Prescribed by a Doctor
• Videos: RxAwareness Campaign
• Tip Card: Preventing an Opioid Overdose
• Additional patient resources:
• Pregnancy and Opioids
• Podcast
• Get the Facts
▶ SAMHSA Resources:
• Opioids
• Finding Quality Treatment for substance Use Disorders
• Clinical Guidance for Treating Pregnant and Parenting Women
With Opioid Use Disorder and Their Infants

•

Medications for Opioid Use Disorder – Executive Summary

▶ Videos on chronic pain and opioids from Oregon Pain Guidance:
• Understanding Pain: What to do about it in less than five minutes
Animation by Hunter Integrated Pain Service (5 minutes)

•

Best Advice for People Taking Opioid Medication
Animation by Dr. Mike Evans (11 minutes)
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Toolkit Part M.

Patient Health Questionnaire (PHQ-9)
▶ The Patient Health Questionnaire (PHQ-9) can be accessed here.
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Generalized Anxiety Disorder seven-item (GAD-7) Scale
Over the past two weeks, how often have you been bothered
by any of the following problems?

Not at all

Several
days

More than
half the days

Nearly
every day

1.

Feeling nervous, anxious, or on the edge

0

1

2

3

2.

Not being able to stop or control worrying

0

1

2

3

3.

Worrying too much about difficult things

0

1

2

3

4.

Trouble relaxing

0

1

2

3

5.

Being so restless that it’s hard to sit still

0

1

2

3

6.

Becoming easily annoyed or irritable

0

1

2

3

7.

Feeling afraid as if something awful might happen

0

1

2

3

Column totals: _________ + _________ + _________
Add totals together: ________________________________

8.

If you checked off any problems, how difficult have those problems made it for you to do your work, take care of things at home, or get along
with other people?

F Not difficult at all

F Somewhat difficult

F Very difficult

F Extremely difficult

Source: Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder.
Arch Intern Med. 2006;166:1092-1097.

1 http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf
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3 depts.washington.edu/anesth/care/pain/telepain/index.shtml.
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